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ABSTRACT 
 
 
Lifestyle and diet have a major effect on the development of colorectal cancer (CRC). 
Dietary habits of Western populations in particular are recognized as a risk factor for CRC. 
However, the mechanisms that mediate the effects of Western-style diet (WD) on 
colorectal tumor development are largely unknown. CRC develops via multiple steps which 
involve genetic changes, such as mutations in growth-regulatory genes, and epigenetic 
alterations, such as CpG island hypermethylation. Lynch syndrome (LS) is one of the most 
common inherited cancer susceptibility syndromes. It is caused by inherited defects of the 
DNA mismatch repair genes (MMR), which together with other genetic and epigenetic 
changes are known to accelerate tumorigenesis. Genetic and epigenetic changes that 
promote the initiation and progression of cancer are called driver events whereas changes 
that accompany the transformation but have no effect on carcinogenesis are referred to as 
passengers. MMR defects are known to accelerate tumor progression in LS but the early 
events leading to polyp formation and the timing and order of the molecular “hits” remain 
unknown. 
 
A long-term feeding experiment with mouse models for LS and sporadic CRC was 
conducted to characterize tumor-promoting changes in normal colonic mucosa caused by 
WD and/or genetic predisposition. Changes in the proteome of histologically normal 
colonic mucosa were monitored at different time points of feeding experiment (5 weeks, 
12, 18 and 21 months) with two high-throughput proteomic methods followed by analysis 
of affected pathways. Data from proteomic analysis indicated that the proteome was more 
consistently changed by diet and aging than by genotype. Overall, 21 out of 26 colonic 
tumors were detected in mice fed with WD. Proteomic analysis indicated disrupted lipid 
metabolism and increased oxidative stress in the normal-appearing tissue in association 
with WD. Moreover, proteome analyses revealed increased cell proliferation and 
decreased apoptotic processes in the normal colon mucosa of mice fed with WD, which 
may promote colorectal tumorigenesis. Finally, proteomic data coupled with measurement 
of bile acids in tissue specimens indicated that WD induces downregulation of intracellular 
bile acid transport, resulting in disrupted bile acid homeostasis which may provide a 
possible mechanism underlying the tumor-promoting effects of the diet. 
 
Studies on sporadic CRC have demonstrated that promoter hypermethylation leading to 
gene silencing can act as an alternative mechanism to mutations in early stages of tumor 
development but its importance in hereditary CRC remains unknown. We analyzed tissue 
specimens gathered during colonoscopy surveillances and colectomies performed on 
human LS mutation carriers to define changes in CpG island methylation that occur at 
different stages of the tumor progression sequence. Methylation changes at different 
stages of tumor progression were analyzed in relation to MMR gene expression, and 
normal tissue biopsies were studied for carcinogenic “fields”. In addition, we aimed to 
clarify the role of CpG island hypermethylator phenotype (CIMP) in the LS-associated 
tumorigenesis. Results indicate that the expression of the MMR protein corresponding to 
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the gene mutated in the germline decreases along with dysplasia but occurs as a relatively 
late event in the tumor progression sequence, suggesting the presence of other somatic 
events that drive neoplastic transformation. Indeed, significant increase in the average 
degree of methylation of two candidate genes (SFRP1 and SLC5A8) was observed in 
normal colonic mucosa biopsies from patients with CRC (high-risk mucosa) when 
compared to those without (low-risk mucosa), indicating a possible carcinogenic field. 
Moreover, methylation was found to increase in LS adenomas and carcinomas along with 
dysplasia. These findings emphasize the importance and early appearance of epigenetic 
alterations in LS-associated tumorigenesis. In summary, the results offer new insights into 
the initiating molecular mechanisms through which Western-style diet and DNA 
methylation contribute to hereditary and sporadic colorectal carcinogenesis.  
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INTRODUCTION 
 
The incidence of colorectal cancer (CRC) is increasing in all industrialized countries and 
dietary habits of Western populations in particular are recognized as a risk factor for CRC 
(1). Based on human and experimental evidence it has been concluded that a Western-
type diet (WD) high in total energy, saturated fats and red meat, in addition with low levels 
of fiber, vitamin D, calcium and folic acid may predispose gut mucosa to CRC. The 
mechanisms that mediate the effects of diet on tumor development are largely unknown. 
CRC develops via progressive accumulation of genetic changes, such as mutations in 
growth-regulatory genes, and epigenetic alterations, such as CpG island hypermethylation 
of tumor suppressor genes. Unhealthy features in WD are likely to induce expression 
changes in key regulatory pathways affecting normal metabolic processes in colonic 
mucosa. 
 
While diet may account for up to 70% of all CRCs (1), genetics and environmental 
influences intertwine. Lynch syndrome (LS) is one of the most common inherited cancer 
susceptibility syndromes and it is associated with inherited defects of the DNA mismatch 
repair genes (MMR) (2), which together with other genetic and epigenetic changes are 
known to accelerate tumorigenesis. Interestingly, the disease phenotype such as age of 
onset and tumor spectrum vary considerably between individuals that carry the same 
germline mutation, suggesting contribution of additional phenotype determinants on risk 
accumulation (3). Apart from genetic alterations, epigenetic effects play a major role in the 
initiation and progression of CRC (4). Epigenetic changes are however potentially 
reversible and can be modified by the environment. These changes can accumulate over 
time due to many environmental factors such as diet. Environmental influences have been 
implicated in LS and epigenetic regulation provides a possible link between genetics and 
variation observed in clinical phenotypes (5). In studies I-II mouse models for LS and 
sporadic CRC were used to study whether and how WD and genetic predisposition may 
separately or together affect the proteome of normal appearing colonic mucosa and thus 
increase the risk for CRC.  
 
MMR defects are known to accelerate tumor progression in LS but the early events 
leading to the formation and the timing and order of the molecular “hits” remain unknown. 
Even though aberrant CpG island methylation affecting tumor suppressor genes has been 
shown to occur frequently in sporadic CRC as well as in colonic adenomas, its importance 
in hereditary CRC remains unknown. CRCs characterized with wide-spread CpG island 
promoter methylation, known as CpG island methylator phenotype (CIMP), are thought to 
form a subtype of tumors with distinct histology compared to tumors derived from the 
traditional adenoma carcinoma sequence (6). In study III, the aim was to define how CpG 
island methylation changes throughout transformation from normal colonic mucosa to pre-
cancerous and cancerous lesions from human LS mutation carriers in relation to MMR 
gene expression and to investigate possible carcinogenic “fields” in the normal appearing 
tissue. Methylation changes in pre-malignant and malignant lesions were studied by 
analyzing the methylation of eight CIMP maker genes and seven tumor suppressor genes 
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that were associated with early colon oncogenesis in a previous study from our group (7). 
Together these investigations emphasize the importance and early appearance of 
epigenetic alterations in LS-associated tumorigenesis and offer new insights to the 
molecular mechanisms underlying the WD-induced risk for CRC. These studies have 
broad implications for further studies addressing early biomarkers in CRC prevention. 
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REVIEW OF THE LITERATURE 
 
COLORECTAL CANCER (CRC) 
 
Epidemiology 
 
Colorectal cancer (CRC) is the third most common cancer and the fourth most common 
cause of cancer related deaths globally (8). More than 1.2 million patients are diagnosed 
with CRC every year (9). In Finland, over 3000 new cases are diagnosed on average each 
year (10). Risk for CRC strongly increases with age and the median age at diagnosis is 
about 70 years. Dietary and lifestyle habits are thought to have a strong impact on CRC 
risk (1). Many epidemiological studies around the world demonstrate major geographical 
variation in CRC incidence and association with obesity, sedentary lifestyle, smoking and 
high consumption of alcohol and red meat (11-16). Protective effect and inverse 
association are suggested between CRC risk and diet rich in vegetables, fiber, dairy 
products and fish (17-20). Highest rates of CRC are found in North America, Western 
Europe, Australia and New Zealand whereas lowest rates are found in developing 
countries. However, rapid increase in the incidence has been reported in previous low risk 
countries, such as Spain, together with economic development and adaption of a so called 
Western lifestyle (11). Additionally, migrants moving from countries with low CRC 
incidence tend to acquire a higher cancer risk similar to host populations (21).  
 
Inherited factors are involved in a substantial proportion of all CRCs. While majority of 
CRCs occur in sporadic manner, 15?35% have been estimated to have a heritable 
background (22). Epidemiologic studies have correlated increased risk with family history 
and a high proportion of all patients have one first to third degree relative with CRC (23). 
Up to 5% of CRCs occur in association with rare highly penetrant Mendelian cancer 
syndromes that are usually inherited in dominant manner (24). Without preventive 
measures the lifetime risk for CRC in these disorders is very high 10-100% (25).  The 
hereditary CRC syndromes are discussed in greater detail in the section Inherited 
predisposition below. 
 
The prognosis of CRC has steadily improved during the past two decades in many high-
income countries, due to improvements in surgery, chemotherapy and screening (11, 26). 
Overall, 5-year survival has reached almost 65% in high-income countries, such as 
Australia, Canada and USA, whereas in low-income countries survival rates remain less 
than 50% (26, 27).  
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Histopathology 
 
Colorectal tumors arise in the colonic epithelium in a multistep process called the 
adenoma-carcinoma sequence which is the classical sample for stepwise progression of 
cancer (Fig. 1). Development of CRC includes multiple well defined histological stages. It 
is thought to originate from hyperplastic or dysplastic colonic crypts that give rise to benign 
and advanced adenomas which are followed by in situ and finally metastatic carcinoma. 
Hyperplastic growth caused by a slightly increased rate of cell division results in patches of 
thicker epithelia with almost normal appearance. When the well-ordered layers of epithelial 
cells become disrupted with slight changes in the cell morphology, the lesions are 
described as dysplastic.  
 
Colonic stem cells located in the base of the crypts give rise to daughter cells during 
mitosis which differentiate into epithelial cells that migrate towards the epithelial surface 
where they undergo apoptosis (28). Aberrant crypt foci (ACF), first described by Bird et al. 
(29), are clusters of hyperplastic or dysplastic colonic crypts that have aberrant 
appearance and growth compared to the surrounding normal colonic mucosa. The colonic 
epithelium is a rapidly renewing tissue which depends on homeostasis of cellular 
proliferation and apoptosis. The ACFs are formed when this balance is lost and therefore 
they are suggested to be the earliest identifiable neoplastic lesions that predispose to CRC 
(30, 31). A more deviant growth of dysplastic cells is called a polyp or adenoma. In the 
colon, several distinct types of polyp histologies are described and all of them have been 
considered as benign changes. 
 
Over 90% of CRCs are thought to arise from adenomatous polyps which are the most 
common form of premalignant precursor lesions. A tumor is considered malignant when 
the dividing cells penetrate through the basement layer of the epithelium and invade to 
underlying tissues. Malignant transition from normal colonic epithelium into adenoma and 
invasive carcinoma involves accumulation of many genetic and epigenetic changes that 
affect genes controlling cell division, apoptosis and DNA repair within the evolving tumor 
cells (32, 33). However, the early molecular events predisposing to polyp formation remain 
unknown. 
 
Presently, the histopathological stage of tumor at diagnosis is the most important 
prognostic factor and early diagnosis is therefore important. Histological classification of 
tumors is made according to invasion depth, lymph node involvement and presence of 
distant metastases (34). Although the recognition of different stages provides valuable 
information for prognosis and therapy, the response to treatment and outcome are not very 
well predicted. Therefore, early biomarkers for CRC could enable identification of patients 
at high risk and improve prognosis and prediction of treatment response. 
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Fig. 1. Key pathways of the adenoma-carcinoma progression sequence. Modified from 
Boland et al. 2009 (35). 
 
 
 
TUMORIGENIC PATHWAYS 
 
Colorectal cancer is a morphologically heterogeneous disease with a variation of clinical 
phenotypes. Molecular and genetic studies have revealed several important signaling 
pathways that are involved in the development of CRC.  The model for the progression 
sequence of genetic changes leading to colorectal cancer was originally proposed by 
Fearon and Vogelstein (36) and since then, the molecular genetic background of each 
morphological step has been relatively well defined. Recognition of molecular pathways 
involved in tumor development are clinically important since they contribute to prognosis 
and treatment response (37, 38). Moreover, the molecular subtypes of colorectal tumors 
can now be classified based on combination of gene expression patterns and mutations, 
chromosomal instability and epigenetic characteristics (39). 
  
  REVIEW OF THE LITERATURE 
16 
 
Chromosomal instability (CIN) 
 
Cell cycle signaling and apoptosis of colonic epithelial cells are tightly regulated by growth 
limiting tumor suppressor genes and growth promoting oncogenes. Chromosomal 
instability (CIN) is a hallmark of tumors arising from the  classical pathway described by 
Fearon and Vogelstein (36), where carcinomas are characterized by alterations in tumor 
suppressor genes such as APC and TP53 and oncogenes such as KRAS. This pathway 
involves 85% of all sporadic CRCs (40).  Tumors that arise via the CIN pathway are often 
aneuploid with high frequency of allelic imbalance and gene copy number variations (41).  
Events of this pathway are illustrated in Fig. 1.  
 
The pathway was discovered through the identification of the APC gene which is known to 
play a role in familial adenomatous polyposis (FAP). Mutations of the APC gene are found 
in 80% of adenomas and carcinomas and they are considered to occur at an early stage in 
sporadic CRC development (42, 43). Inactivating mutations often lead to truncation of the 
APC protein which causes inability of APC to recognize and bind ?-catenin in the 
cytoplasm. This increases the concentration of cytoplasmic ?-catenin and results in 
translocation of ?-catenin into the nucleus (44). Nuclear ?-catenin upregulates the Wnt 
signaling pathway which reduces cell differentiation and apoptosis and induces 
proliferation and invasive growth. Even though inactivation of APC is a common event in 
colonic adenomas and carcinomas, it is seldom found in sporadic ACF. Therefore, 
upregulation of the Wnt signaling through mutated APC is regarded as the mechanism that 
drives malignant transformation from ACF to adenoma in sporadic CRC (43). 
 
In addition to APC inactivation, mutations that cause activation of the KRAS oncogene 
occur at very early stages of colorectal carcinogenesis and are found in 30-50% of 
sporadic CRCs and advanced adenomas (45). Interestingly, KRAS mutations are found in 
up to 95% of early dysplasia including ACF and hyperplastic polyps (46, 47). However, 
they are considered to be insufficient to cause malignant transformation by themselves 
and need additional driver mutations for cancer to develop (48). KRAS is a GTP binding 
protein that activates a large number of signal transduction pathways which promote 
hyperplastic growth and suppress differentiation of colonic epithelial cells (49). It is 
responsible for the transduction of mitogenic signals from the cell surface epidermal 
growth factor receptors (EGFR). Consequently, activation of KRAS caused by mutations 
results in constant growth signaling.  
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Additional molecular events in the CIN phenotype include loss of function of the TP53 
tumor suppressor gene, which encodes p53 protein. Mutations in TP53 occur in 
approximately 70% of all sporadic CRCs. p53 has a crucial role in controlling the cell cycle 
and maintaining genomic stability (50).  When DNA damage occurs, p53 points out the 
errors to the caretaker proteins for reparation or induces apoptosis if the damage is too 
extensive to be repaired (51). In addition to DNA damage, it is activated by ultraviolet (UV) 
radiation, oxidative stress, chemicals and viruses among others (52). Inactivation of TP53 
drives carcinogenesis from non-invasive to invasive state and occurs at a later stage of 
tumor development during the progression from advanced adenoma to carcinoma in 
sporadic CRC (53).  
 
Microsatellite instability (MSI) 
 
Microsatellite instability represents an alternative key pathway in the development of CRC 
(Fig. 1). Microsatellites are repeats of short polymorphic nucleotide sequences in the DNA 
that are scattered throughout the genome and constitute a unique profile of individual DNA 
fingerprints (54, 55). Microsatellite sequences are tandemly repeated from 3 to 100 times 
and locate often in the non-coding regions. Microsatellite instability (MSI) results from 
defects in the mismatch repair (MMR) function responsible for post-replicative 
proofreading and editing of errors that arise during DNA replication. Failure of the MMR 
system causes accumulation of spontaneous point mutations and increased frequency of 
insertion/deletion mutations in the genome (56). Tumors characterized with MSI have 100 
to 1000 fold increase in mutation rate when compared to normal cells (57). Microsatellite 
sequences in particular are vulnerable to accumulate mutations caused by replication 
errors since the polymerase complex is prone to make mistakes in repeated regions. 
 
MMR defects in humans were originally identified in the early 1990s in relation to the 
discovery of the molecular genetic background of hereditary non-polyposis colon cancer 
(HNPCC), more recently named as Lynch syndrome (LS) (58, 59). The four main genes 
identified as the primary cause of MMR defects are mutL homologue 1 (MLH1), mutS 
homologue 2 (MSH2), mutS homologue 6 (MSH6) and postmeiotic segregation increased 
2 (PMS2). MSI phenotype is a hallmark of LS tumors but in addition it is detected in 
approximately 15-20% of sporadic CRCs. Defects in MMR are mainly caused by mutations 
that result in malfunction or complete loss of a MMR protein. Alternatively, silencing of 
MLH1 caused by promoter hypermethylation is often seen in sporadic CRC (60). Loss of 
MLH1 or MSH2 is associated with complete inactivation of MMR function, whereas defects 
in other MMR proteins often cause only partial MMR deficiency (61). In sporadic CRC, 
inactivation of MMR is mainly proposed to accelerate rather than initiate tumor 
progression, but the exact timing of MMR inactivation during the progression sequence 
remains unclear (62).  
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Tumors with MSI show less cytogenetic abnormalities and aneuploidy compared to tumors 
that arise from the CIN pathway. In addition, they display induced frequency of mutations 
in genes such as BRAF and TGF-? and reduced frequency of mutations or allelic losses of 
genes typically mutated in the CIN phenotype (63, 64). MSI tumors are typically localized 
in the proximal region of the colon and have distinctive histological features including poor 
differentiation, lymphocytic infiltration and mucinous histology (65). Association of tumor-
infiltrating lymphocytes is thought to result from an anti-tumoral immune response induced 
by MMR deficiency and high genomic mutation load, which is recognized by the immune 
system (66, 67). In immunohistochemically stained tumor sections, MSI tumors show loss 
of at least one MMR protein expression in at least 90% of lesions (68). 
  
Knowledge about the MMR status of tumors provides valuable clinical information related 
to prognosis and therapy response. Overall, cancers that arise via the MSI have a better 
prognosis than MMR competent tumors (69). Moreover, MSI tumors do not respond to 
adjuvant therapy with 5-fluorouracil whereas improved response is achieved when treated 
with irinotecan-based chemotherapy (70, 71). 
  
CpG island methylator phenotype (CIMP) 
 
Altered patterns of gene expression in tumor cells are driven by many genetic and 
epigenetic changes (72). Epigenetic modifications are biochemical changes in the DNA 
and chromatin structure that regulate gene expression without altering DNA sequence 
itself. DNA methylation is a vital mechanism for normal cell function and it plays a key role 
in processes such as cell differentiation, embryonic development, X chromosome 
inactivation and genomic imprinting (73, 74). However, aberrant DNA methylation patterns, 
hypermethylation and hypomethylation, have been associated with many disease states. 
In normal somatic cells majority of methylation occurs in the cytosine residues of the CpG 
nucleotides. Hypermethylation of sequences enriched with CpG dinucleotides, called CpG 
islands, located around the transcription start site is associated with silencing of the 
adjacent gene (75).  
 
Alterations in DNA methylation patterns are intensively studied in relation to CRC. 
Sporadic CRCs often show a decrease in global genomic DNA methylation content (76). 
However, increase in CpG island methylation affecting multiple tumor suppressor genes is 
observed in a subset of CRCs, giving rise to CpG island methylator phenotype (Fig. 1) (6). 
Hypermethylation in promoter regions of tumor suppressor genes is known to 
downregulate their expression and predispose to cancer (6). In addition to CRC, tumors 
with CIMP have been described in various cancers of other organs such as breast (77), 
lung (78), endometrium (79), bladder (80) and kidney (81). 
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Since tumors with CIMP are characterized by distinct clinical and molecular features such 
as proximal tumor location, poor differentiation, high rates of MSI and BRAFV600E 
mutations, they are thought to represent a distinct pathway of colorectal carcinogenesis 
(82, 83). CIMP was originally recognized as a characteristic of non-adenomatous mucosal 
lesions called sessile serrated adenomas or polyps. These tumors resemble benign 
hyperplastic polyps but with increased dysplasia, irregular crypt architecture and a 
significant malignant potential. Moreover, CIMP has been associated with 
hypermethylation of MLH1 promoter region which induces MMR deficiency and MSI as a 
consequence (84, 85), whereas large chromosomal aberrations are less frequently 
observed (86, 87). 
 
Methylation markers for classification of CIMP have not been standardized. This has led to 
discrepancies between studies and difficulties in defining the borderline between CIMP-
positive and non-CIMP tumors (88, 89). Moreover, inconsistences in different marker 
panels, thresholds and analytical methods used for classification have caused difficulties in 
assessing the value of CIMP in predicting prognosis and therapy response. Substantial 
effort has been made to identify accurate markers for different CIMP subtypes in CRC. 
Weisenberger et al. identified a robust panel of five CIMP marker genes (CACNA1G, 
IGF2, NEUROG1, RUNX3 and SOCS1) that define a heavily methylated subset of CRCs 
with MSI and BRAFV600E mutations (84). This panel is the most commonly used panel for 
CIMP and it classifies tumors with 3/5 or more methylated promoters as CIMP-positive. 
Ogino et al. (90) proposed three additional genes (CDKN2A, CRABP1 and MLH1) to this 
panel together with three suggested categories: CIMP-high with 6/8 to 8/8, CIMP-low with 
1/8 to 5/8 and non-CIMP with 0/8 hypermethylated promoters. Molecular and clinical 
characteristics of the intermediately methylated CIMP-low group vary among different 
studies and remain unclear. In comparison to the CIMP-high group, CIMP-low tumors have 
increased frequency of KRAS mutations whereas BRAF mutations and MSI are less 
frequent (82).  
 
Aberrant methylation is known to occur at early stage of colorectal tumor development (6). 
Genomic DNA methylation has been suggested to accumulate in normal colonic mucosa 
in age-dependent manner which could be the earliest changes marking the increased risk 
for CRC (91). Moreover, CIMP together with BRAF and KRAS mutations has been 
reported in hyperplastic polyps and adenomatous lesions whereas MLH1 hypermethylation 
and MSI occur at a later stage of tumor progression (92-94). The cause and molecular 
mechanism of aberrant DNA methylation and CIMP remain unknown, although several 
possible factors have been reported. For instance, increased expression of DNMT3B 
together with increased methylation has been shown to occur during progression of CRC 
(95). Additionally, the effect of lifestyle and dietary factors has been investigated in several 
epidemiological studies and consumption of a low-folate diet, smoking and high alcohol 
consumption have been associated with CIMP-high CRC and BRAF mutation (96, 97). 
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INHERITED PREDISPOSITION 
 
Inherited factors are involved in a substantial proportion of all CRCs (Fig. 2). Even though 
CRC is often divided into sporadic and familial forms, it is noted that even in sporadic 
CRCs genetic factors may have an influence although currently identified genetic factors 
account for only up to 10% of all CRCs (98). Genomic-wide association studies (GWAS) 
performed in large cohorts of patients with CRC and healthy controls have identified 
approximately 40 common low-penetrance alleles that associate with a small increase in 
CRC risk (99). Consequently, genetic background can provide additional information on 
the cumulative cancer risk together with age and family history (100).  
 
 
 
Fig.2. Genetic predisposition to colorectal cancer.  
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Hereditary syndromes 
 
Colorectal cancer syndromes are divided into hereditary polyposis syndromes 
characterized by the development of multiple colorectal polyps and non-polyposis 
syndromes in which only few or no polyps occur. Each syndrome is diagnosed and 
classified based on genetic, pathological and clinical features. Hereditary CRC develops 
typically two to three decades earlier compared to sporadic CRC.  Increased risk for 
cancer in hereditary syndromes is caused by inherited defects in genes that regulate 
growth regulatory processes or DNA repair in conjunction with somatic events that cause 
the remaining wild-type allele to become inactivated. In hereditary cancer, the inactivation 
of the first allele of a predisposing gene is caused by inherited germline mutations whereas 
the wildtype allele becomes somatically inactivated in the target tissue by genetic or 
epigenetic events (101). Predisposing genes for many of these syndromes have been 
identified, and testing for inherited mutations in families at high risk including predictive 
testing in asymptomatic family members has become routine. International guidelines have 
been established to aid the identification and diagnosis of hereditary cases and screening 
for precursor lesions is utilized in surveillance and early detection of tumors in familial 
cases. 
 
Lynch syndrome 
 
Lynch syndrome is the most prevalent form of hereditary CRC with a share of 
approximately    3% of all CRCs and autosomal dominant transmission pattern (102). The 
predisposed individuals have significantly increased lifetime risk for CRC (10-70%) and 
endometrial cancer (12-55%), depending on which gene is affected (103-105). Moreover, 
the syndrome is characterized by increased risk for other extracolonic manifestations such 
as cancers of the urinary tract, ovarian, stomach, pancreas, small bowel and brain (106). 
Clinical features of CRC include early onset (mean 45 years)  and location in the proximal 
colon (70-80%) (107). Histologically tumors are characterized as mucinous and poorly 
differentiated with villous components and lymphocytic infiltration (108). The presence of 
tumor-infiltrating lymphocytes, most probably induced by anti-tumoral immune response 
caused by the high genomic mutation load, is thought to contribute to the improved 
prognosis of LS compared to sporadic CRC (66, 67).  
 
Before the genetic basis of the syndrome became established, the Amsterdam criteria I 
(AC I) were set in 1991 to standardize the clinical guidelines and aid diagnosis (109) 
(Table 1). These criteria were amended in 1999 to take into account extracolonic 
manifestations (AC II) (110). After MSI was recognized as a characteristic of LS tumors, 
the Revised Bethesda Guidelines were established in 1996 to provide guidelines including 
MSI testing of tumors for identification of LS (65) (Table 1). Similarly to sporadic CRC, 
colorectal tumors in LS seem to evolve through the adenoma-carcinoma sequence. The 
risk for CRC can be managed reasonably well by repeated colonoscopies and 
polypectomies (111). Intensive colonoscopy surveillances are recommended for LS 
patients starting at the age 25 with a two-year interval (112). Since LS mutation carriers 
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have a relatively high risk for synchronous or metachronous tumors, total or subtotal 
colectomy have been suggested as the primary choice of operation for patients with CRC 
(113). 
 
Majority of LS causing heterozygous germline mutations are found in the DNA mismatch 
repair genes MLH1 and MSH2 whereas mutations in MSH6, PMS2 and MLH3 account for 
minority of cases (2). MMR mechanism maintains DNA integrity by detecting and repairing 
nucleotide mismatches and small insertion/deletion loops that arise during DNA replication 
and recombination. Inactivation of the remaining wild type allele in somatic cells results in 
loss of the encoded protein and MMR malfunction which causes accumulation of 
replication errors in the genome leading to MSI (114). The progression from polyps to 
carcinomas is accelerated in LS (2-3 years) compared to sporadic CRC (6-10 years) due 
to defective MMR that results in accumulation of mutations and subsequent selection and 
clonal expansion of mutated cells with growth advantage (115). 
 
The wild type allele can become somatically inactivated through deletion, point mutation or 
CpG island hypermethylation. Somatic inactivation caused by hypermethylation primarily 
occurs in the promoter region of the MLH1 gene (116, 117). Large genomic 
rearrangements within MLH1 and MSH2 have also been reported to cause loss of the 
respective protein, resulting in LS phenotype in patients that lack conventional MMR gene 
mutations (118). Over 3000 unique sequence variants have been reported for the MMR 
genes in the International Society of Gastrointestinal Hereditary Tumors (InSiGHT) 
database (http://insight-group.org/), out of which missense mutations are the most 
common type of variation in addition to insertions/deletions.  
 
Age of onset and the risk of developing various types of cancer vary depending on which 
MMR gene is mutated (119). Moreover, considerable differences in the clinical phenotype 
and age of onset exist even in patients with the same pathogenic germline mutation (3). 
Patients with the same mutation may express considerable differences in their clinical 
phenotype and age of onset or in rare cases live happily ever after without having to 
endure a cancer diagnosis. This raises a question about other yet unknown factors, such 
as dietary effects, that may together with the genotype have a significant effect on cancer 
risk. 
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Table 1. Guidelines for Lynch syndrome diagnosis. 
                   
Amsterdam?I?II?Criteria?for?diagnosis?of?Lynch?syndrome?
At?least?three?relatives?with?histologically?verified?LS?associated?cancer1?are?required?of?which:?
?One?is?a?first?degree?relative?of?the?other?two?
?At?least?two?successive?generations?are?affected?
?At?least?one?of?the?relatives?with?CRC?is?diagnosed?at?<50?years?of?age?
FAP?has?been?excluded?in?any?CRC?cases?
?Tumors?should?be?verified?for?pathology?
Bethesda?Guidelines?for?testing?MSI?in?colorectal?tumors?
MSI?testing?is?justified?when:??
CRC?is?diagnosed?at?<50?years?of?age?
Synchronous?and?metachronous?CRC?or?other?LS?associated?cancers?diagnosed?at?any?age?
CRC?with?MSI?high?histology2?diagnosed?in?a?patient?<60?years?of?age?
CRC?or?LS?associated?tumor?is?diagnosed?<50?years?of?age?in?at?least?one?first?degree?relative?
CRC?or?LS?associated?tumor?is?diagnosed?at?any?age?in?two?first??or?second?degree?relatives?
MSI?is?classified?as?
MSI?high?when?2?5?of?markers?indicate?MSI?
MSI?low?when?only?1?out?of?5?markers?indicate?MSI?
MSS?when?none?of?five?markers?indicate?MSI?          
1LS?associated?cancers?include?CRC?and?cancers?of?endometrium,?stomach,?ovary,?ureter?or?renal?pelvis,?small?bowel,?brain,?
hepatobiliary?tract?and?skin?
2MSI?high?histology?refers?to?the?presence?of?tumor?infiltrating?lymphocytes,?mucinous?or?signet?ring?differentiation?or?
medullary?growth?pattern?
 
 
Approximately 90% of mutations are found in MLH1 and MSH2 (2). Patients with MLH1 
and MSH2 mutations have relatively early age of onset (40-50 years) and increased risk 
for the whole spectrum of LS associated cancers with the distinction that MSH2 mutation 
carriers seem to have a moderately increased risk for extracolonic cancers (119, 120). In 
addition to germline mutations, constitutional epimutations have been reported in a small 
number of individuals meeting the clinical criteria of LS (121). Epimutations are defined as 
heritable alterations in gene activity which are caused by epigenetic changes, such as 
aberrant DNA methylation, rather than changes in the DNA sequence itself. These cases 
are characterized with constitutional methylation and transcriptional silencing of one of the 
alleles in the normal tissue which predisposes to the development of LS-like phenotype 
(122).  
 
Secondary epimutations that cause hypermethylation and inactivation of MLH1 and MSH2 
have been associated with adjacent genetic alterations and demonstrate dominant 
inheritance whereas constitutional hypermethylation of MLH1 as a primary event shows 
non-Mendelian inheritance patterns (123). Loss of MSH2 expression is most often caused 
by germline mutations in MSH2 gene, however 10% of cases are characterized with a 
heritable epimutations caused by deletions of the 3’ end of EPCAM gene located upstream 
of MSH2 which results in hypermethylation of the MSH2 promoter (124-126). Deletions 
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result in removal of the transcription termination signal of the EPCAM gene which causes 
abnormal transcriptional elongation of the EPCAM transcript into MSH2. The clinical 
phenotypes of patients with MSH2 and EPCAM mutations are similar with a distinction of 
decreased lifetime risk for extracolonic cancers in patients with EPCAM mutations but 
increased risk for endometrial cancer in cases where  EPCAM mutation is located close to 
MSH2 (127).  
 
Patients with MSH6 and PMS2 mutations are less frequent and represent more distinct 
clinical phenotypes. Patients with MSH6 mutations have a later age of onset and 
substantially lower cumulative risk for CRC (10-22%) and other cancers when compared to 
MLH1 and MSH2 mutation carriers (128). However, female MSH6 mutation carriers have 
been suggested to have a higher risk for endometrial cancer compared to carriers with 
other MMR gene mutations (129). MSH6 deficient tumors show lower level of MSI in 
general with consistent MSI only in association with mononucleotide repeat sequences 
(130).  Clinical phenotype caused by germline mutations in PMS2 is described as 
attenuated with later age of onset (131). The risk of developing CRC and other LS 
associated cancers is significantly lower (~20% and ~15% for CRC and endometrial 
cancer, respectively) in PMS2 mutation carriers (132). In rare cases, germline mutations in 
MLH3 and MSH3 have been associated in disease phenotype but their pathogenic role 
remains unclear (133-135). Mutations in these genes have been suggested to behave as 
low-risk alleles that contribute to CRC risk in LS patients, mostly together with other low-
risk variants of MMR genes.   
 
Currently, identification of LS involves tumor analysis including MSI testing and/or 
immunohistochemical staining (IHC) of MMR proteins, and BRAF mutation testing in MLH1 
negative cases (136). BRAFV600E mutation is associated with MLH1 promoter 
hypermethylation in sporadic MSI-CRC and therefore it is known to reduce the possibility 
of LS (137). Germline genetic testing involves DNA sequencing and gene arrangement 
analysis of all coding exons and exon-intron boundaries of MMR and the EPCAM genes. 
However, genetic testing fails to identify a germline MMR gene mutation in up to 30% of 
families that have LS-like phenotype with tumors that manifest MSI and absence of MMR 
protein (138). While a substantial proportion of such cases appears to be explained by two 
somatic mutations of MMR genes, it is possible that some of these patients have germline 
mutations affecting MMR gene expression in promoters or intronic sequences that are not 
detected by currently used methods. Moreover, alternative unknown mechanisms that 
inactivate MMR and cause similar clinical phenotypes of LS may exist.  
 
Furthermore, ~50% of patients with family history of CRC that meet ACI but have no 
evidence of MSI or detectable MMR deficiency in observed tumors, are classified to have 
familial colorectal cancer type X (FCCX) (139). These patients have similarly increased 
risk for CRC with slightly higher age of onset and no association with extracolonic tumors. 
Consequently, “type X” refers to the largely unknown genetic etiology and it is likely that 
FCCX is a group of conditions with heterogeneous genetic background. Recent studies 
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have identified mutations associated with FCCX in several different genes which seem to 
affect only one or few families (e.g BMPR1A, RPS20 and SEMA4A) (140-142). 
 
Familial adenomatous polyposis (FAP) 
 
Polyposis syndromes are classified based on clinical features in combination with the 
pathology of the polyps. Familial adenomatous polyposis (FAP) is inherited in autosomal 
dominant manner and it is the most common polyposis syndrome accounting for less than 
1% of all CRCs (143). It is characterized by the development of hundreds of colorectal 
adenomatous polyps beginning in late childhood or early adolescence and extremely high 
risk (~100%) for early-onset CRC  (144). Adenomatous polyps, most commonly described 
as tubular adenomas, develop throughout the colon with a slightly higher incidence in the 
distal parts. About half of all patients develop adenomas by the age 15 and 95% by the 
age 35 (145). In addition to colorectal polyps, patients are predisposed to duodenal polyps 
and adenomas, but the risk for duodenal cancer is substantially lower compared to CRC 
risk (<10-15%) (146). Moreover, the risk for cancer in other organs such as the brain, liver 
and thyroid is slightly increased (147).  
 
The disease is caused by pathogenic heterozygous germline mutations in the 
adenomatous polyposis coli (APC) tumor suppressor gene, which was first described in 
1991 (148, 149). The development of tumors follows the inactivation of the remaining 
wildtype allele by somatic mutations, which is considered an early event in CRC 
tumorgenesis. Indeed, APC plays a critical role in the etiology of sporadic CRC, and 
mutations in the APC gene are found in 70% of all CRCs. Tumorigenic pathway that 
follows inactivation of the wild type allele in FAP resembles sporadic colorectal 
carcinogenesis, where tumor development is often driven by mutations in KRAS and TP53 
(150).  
 
APC is a large gene with 15 exons that encode a protein of 2843 amino acids that plays a 
significant role in the Wnt signaling pathway (151). The APC protein negatively regulates 
?-catenin oncoprotein by directing the ubiquitination and degradation of ?-catenin in the 
cytosol. In the absence of APC, ?-catenin migrates and accumulates into the nucleus and 
up regulates the transcription of genes involved in cell cycle entry, proliferation, 
differentiation and apoptosis (152). Moreover, APC has a dual role in stabilization of 
microtubules in the nucleus which contributes to chromosomal stability (153).  
 
More than 1100 of likely pathogenic mutations and over 3000 APC variants have been 
reported in the InSiGHT database (http://www.lovd.nl/apc). Of all pathogenic mutations 
95% are nonsense mutations and small insertions or deletions that lead to truncated 
protein (154). The severity of the syndrome depends on which region of the APC gene is 
mutated; germline mutations associated with the classical FAP phenotype locate in exons 
5-8, 9-14 and the first half of the large exon 15 (155). The region between codons 1250 
and 1464 of exon 15, called the mutation cluster region (MCR), is the most common target 
of both germline and somatic mutations (143). Most of the pathogenic APC mutations are 
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inherited, but 11-25% of FAP cases are sporadic with no family history of disease caused 
by de novo mutations (156). 
 
Mutations that are localized in either end of the gene or in the alternatively spliced region 
of exon 9 are associated with a less severe phenotype known as attenuated FAP (AFAP) 
(157). Mutations that cause AFAP encode almost full-length protein which provides 
explanation for the milder phenotype. AFAP is characterized by a reduced number of 
colorectal polyps (10-100), a later age of onset and lower CRC risk (up to 70%). Currently, 
direct sequencing of all 15 exons of the APC gene is the standard method for mutation 
detection and accounts for >85% of all detected mutations including point mutations and 
small insertions and deletions (158). The remaining mutations are large deletions or 
duplications that can be detected by other methods such as multiplex ligation-dependent 
probe amplification (MLPA) (159). 
 
Even though genotype-phenotype correlation is observed, considerable variation in clinical 
phenotype exists among individuals carrying the same germline mutations which suggests 
contribution of alternative mechanisms and/or environmental effects (160). Moreover, in up 
to 30% of FAP patients no germline mutations are detected (161). Regulation of the 
absolute gene expression and differences in allele-specific expression (ASE) may play a 
role in phenotypic variability in cases with and without pathogenic mutations but the exact 
mechanisms remain unknown (162). 
 
Intensive surveillance is essential for patients with FAP since without surveillance and 
timely treatment, one or several of the adenomas will inevitably progress into cancer. The 
regular surveillance consists of sigmoidoscopy or colonoscopy every 1-2 years depending 
on the findings, starting at age 10-15 (163).  
Surgery is the only effective treatment for FAP that prevents malignant changes in 
colorectal adenomas. Restorative proctocolectomy (RPC) is recommended as the primary 
choice for prophylactic surgery for FAP patients (164). Establishment of worldwide 
polyposis registries and surveillance programs has reduced CRC mortality substantially 
and other malignancies are currently the main cause of death in FAP patients (165, 166). 
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LIFESTYLE AND DIETARY RISK FACTORS  
 
Environmental factors have a profound influence on the development of cancer whereas 
only a minority of cases are of hereditary origin (Fig. 3). Lifestyle and diet are known to 
contribute to cancer risk which makes them important issues to be considered by the 
general population and the medical community. Rates of different types of cancers varies 
geographically, highlighting the role of environmental factors in the development of cancer 
in general (167). Diet, together with age and hereditary factors, is noted to be the most 
important risk factor for CRC in particular, since the colorectal mucosa is in direct contact 
with dietary components and constantly exposed to diet-induced metabolic and 
physiological changes (Fig. 4) (9). However, addressing the mechanisms between diet and 
colorectal cancer has proven to be difficult due to the complex interactions between 
nutrients, genes and metabolism. Up to 50-70% of CRCs have been estimated to arise 
due to lifestyle and dietary effects and to be preventable by changes in these habits (168, 
169). At present, recommendations for CRC prevention are based on hypotheses and 
epidemiological evidence linking lifestyle and dietary factors with CRC incidence since the 
complex network of the causes of CRC have not been completely unraveled. The main 
lifestyle and dietary risk factors that are thought to contribute to CRC risk are introduced in 
this chapter. 
 
 
 
 
Fig. 3. Effect of hereditary and environmental risk factors in the development of cancer. 
Modified from Anand et al. 2008 (167). 
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Fig. 4. Lifestyle and dietary risk factors for CRC. Modified from the AICR/WCRF Colorectal 
Cancer Report (1). 
 
 
Smoking and alcohol consumption 
 
High alcohol consumption appears to be a major risk factor for gastrointestinal tumors. 
Acetaldehyde, which is the primary metabolic product of ethanol, is a highly cytotoxic 
compound with carcinogenic and mutagenic activity which can damage colorectal mucosa 
and elevate cell proliferation (170). Alcohol is known to act as a direct inducer of 
cytochrome P-405 2E1 (CYP1A2) enzyme which is involved in metabolizing unknown 
chemical compounds in the body and increasing the production of free radicals as side 
products. In addition, alcohol causes reduced absorption of other B vitamins (B1, B2, B12, 
folate) which increases vulnerability to oxidative stress (171). Alcohol has been estimated 
to contribute to approximately 17% and 4% of total CRC incidence in males and females, 
respectively, when consumption exceeds the recommended upper limit (two drinks a day 
for men with about 24 g alcohol, one for women with about 12 g alcohol) (172). 
In addition to alcohol consumption, cigarette smoking is thought to be another major 
lifestyle factor related to increased CRC risk. In a previous study, positive association was 
observed between smoking and CRC risk, but induction period of 30 years of smoking was 
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required for significant association (173). Smoking was also found to double the risk for 
colorectal adenomas. Tobacco smoke contains carcinogenic compounds such as 
acetaldehyde, benz-pyrenes, aromatic amines and N-nitrosamines that can bind DNA and 
disrupt normal cell functions (174). 
 
Obesity and physical activity 
 
Obesity, defined as body mass index (BMI, kg/m2) greater than 30, is associated with 
increased CRC mortality (175). Individuals with BMI higher than 30 show 19% increased 
risk for CRC when compared to those with BMI between 20 and 25 (176). Increased 
wealth and modernization in the Western countries have been associated with the 
increased prevalence of overweight individuals and increased incidence of CRC. Indeed, 
epidemiological evidence demonstrates a higher risk for CRC in association with excess 
intake of total energy (177, 178).  
 
Interestingly, exercising one hour per week was associated with a lower prevalence of 
colonic polyps and adenomas when compared to people who exercised less or not at all in 
a multiethnic screening cohort (179). A previously conducted multi-cohort study 
demonstrated a 24% decrease in CRC risk in physically active individuals when compared 
with individuals with a more sedentary lifestyle confirming the inverse association between 
physical activity and CRC in both men and women (180). Moreover, it has been estimated 
that 30-60 min of moderate to vigorous daily exercise is needed to protect against CRC 
(181). Physical activity is thought to improve metabolic efficiency and tissue oxygenation 
which leads to reduced body fat and insulin levels, whereas the lack of exercise is 
associated with low-grade chronic inflammation and high levels of estrogen and insulin 
which are known to promote excess proliferation of epithelial cells (182). Moreover, 
physical inactivity increases the gastrointestinal transit time and the duration of direct 
contact between possible carcinogens and the epithelium (167). 
 
High consumption of dietary fat has been associated with increased prevalence of obesity 
due to increased intake of energy dense foods (183). Epidemiological studies concerning 
dietary fat consumption in relation to CRC incidence show discrepancies and the 
association has not been proven (184, 185). It is possible, that increased consumption of 
certain types of fatty acids may be more relevant for the development of CRC than the 
total amount of dietary fat. For example, consumption of n-3 polyunsaturated fatty acids 
have been suggested to associate inversely with CRC (186, 187). Polyunsaturated n-6 
fatty acids act as substrates for eicosanoid production, which can activate pro-
inflammatory pathways that promote colon carcinogenesis (186). Therefore, the ratio of n-
6 to n-3 fatty acids has been suggested to be particularly important. Moreover, 
consumption of high-fat diet is known to result in significantly higher excretion of 
secondary bile acids in the gastrointestinal tract in order emulsify the increased level of 
dietary fat (188). Bile acids are implicated to be important in the etiology of CRC since they 
are known to induce reactive oxygen/nitrogen species (ROS/RNS) which lead to increased 
DNA damage and stimulation of apoptosis (189). 
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Multiple biological processes are known to contribute to the obesity and cancer 
relationship. Increased body fat is known to have a direct effect on physiological hormonal 
levels such as insulin, leptin, estrogen and insulin like growth factor 1 (IGF1), which can 
promote insulin resistance, inflammation and decreased cellular apoptosis (190). 
Abdominal fat, in particular, is known to increase insulin resistance and subsequent 
hyperinsulinemia which increases risk for CRC (1). The balance and interaction between 
all of these processes take part in determining the physiological cancer risk. 
 
Western-style diet 
 
Notable geographical variation in worldwide CRC incidence suggests significant 
contribution of lifestyle and dietary factors to the etiology of the disease. In addition to age 
and hereditary factors, dietary habits of Western population in particular are considered to 
promote development of CRC. Positive correlation between CRC incidence and a typical 
Western-style diet was first reported in the beginning of the 1980s (191). This risk was 
acknowledged in 2007 by the World Cancer Research Fund (WCRF) and The American 
Institute for Cancer Research (AICR) (192). Based on epidemiological evidence and 
cohort studies it was concluded that high intake of total energy, red and processed meat 
and high consumption of alcohol together with low intake of fiber, calcium, vitamin D, folic 
acid and selenium associates with increased risk for CRC. On the contrary, high intake of 
dietary fiber, non-starchy fruits and vegetables and fish were reported to decrease CRC 
risk. Moreover, consumption of a Western-style diet characterized by high intake of fat, 
sugar, red and processed meat was shown to decrease survival and increase risk for CRC 
re-occurrence when compared to diets including more fiber and less fats and sugar (193).  
 
In 2011, a multicenter cohort study based on the European Prospective Investigation into 
Cancer and Nutrition (EPIC) data revealed significant inverse association between intake 
of cereal fiber and whole grains and CRC, strengthening the evidence that consumption of 
dietary fiber can prevent CRC (194). Fiber is thought to play an important role in binding 
and carrying waste products and cytotoxic compounds such as bile acids in the 
gastrointestinal tract, accelerating intestinal transit and reducing the time of exposure to 
luminal carcinogens (195). Butyrate, which is an intestinal microbiota metabolite of dietary 
fiber, has been shown to have cancer-preventive effects through its ability to modulate of 
cell-cycle arrest and apoptosis (196, 197). Butyrate is a short-chain fatty acid that is 
produced in the colonic lumen during bacterial fermentation of dietary fiber. Interestingly, 
butyrate producing bacteria have been shown to be underrepresented in CRC patients 
(198). 
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Considerable number of studies have identified high consumption of red and processed 
meat as a risk factor for CRC. Underlying mechanisms mainly thought to explain this 
association include increased fat intake together with meat, mutagens formed during 
cooking at high temperatures (heterocyclic aromatic amines, polycyclic aromatic 
hydrocarbons), heme iron and nitrite (199). Indeed, dietary heme has been shown to 
promote formation of colonic neoplastic lesions in rats (200). 
 
Many epidemiologic studies suggest inverse effect of calcium and vitamin D intake on 
CRC risk, however results are inconsistent (1). Studies on animal models have shown 
them to contribute in regulating anti-neoplastic processes that suppress hyperproliferation 
and induce differentiation and apoptosis of colonic epithelial cells (201). Extensive 
evidence from in vitro studies support calcium and vitamin D to have direct anti-
proliferative and apoptosis-inducing effects on normal colonic epithelial cells (202-204). 
Moreover, anti-proliferative effects of calcium are thought to be at least partially caused by 
its capability to bind dietary fatty acids and bile acids which reduces the carcinogenic 
effects of these compounds on colonic mucosa (205). However, in order to understand the 
combinational effect of calcium and vitamin D in chemoprevention, the molecular 
mechanisms that support their interplay and mediate protection against CRC remain to be 
elucidated.  
 
Folate is a term used for a group of essential B9 vitamin compounds that maintain 
genomic stability by regulating DNA biosynthesis, repair and methylation. Folate is present 
at high concentrations in green leafy vegetables whereas folic acid (FA) is a synthetic 
oxidized form of folate that is primarily used in supplements. Limited folate results in 
decreased DNA pre-cursors purine and pyrimidine that are required for DNA synthesis and 
repair (206, 207). Folate deficiency accelerates carcinogenesis by causing deficiencies in 
these processes and is implicated in several cancers including CRC (208). In addition, 
deficiency causes altered cytosine methylation which can lead to global hypomethylation 
and/or gene-specific changes in methylation patterns that can cause inappropriate 
activation of proto-oncogenes (209). The role of folate and FA in CRC development 
remains controversial. Evidence from majority of epidemiological studies suggest high 
dietary intake of folate and subsequently elevated blood concentration to significantly 
reduce the risk of developing colorectal neoplasias (210-212). However, more recent data 
from clinical trials indicate that excessive intake of synthetic FA from supplements may 
actually increase the risk for CRC by accelerating the growth of pre-neoplastic lesions 
(213, 214). Since folate acts as a rate limiting factor for DNA synthesis and  potential 
growth factor, administering high doses of FA at an inappropriate time may accelerates the 
growth of existing neoplastic cells (215).  
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MOUSE MODELS IN CRC STUDIES 
 
The laboratory mouse (Mus musculus) is one of the best and most commonly used 
experimental model in biomedical research because of the availability of its genomic 
information and well-established techniques to generate transgenic and knock-out mice by 
targeted mutagenesis. These models are essential to study the mechanisms of 
pathogenesis and to establish therapeutic and preventive measures for cancer and other 
diseases. Different models have been developed to study alternatively expressed genes 
and pathways related to CRC to provide understanding of the human conditions. 
Genetically engineered mouse strains have been developed for hereditary colorectal 
cancer syndromes such as LS and FAP. Colon cancer and polyposis phenotypes studied 
in mice have revealed many similarities with disease phenotypes in human. 
 
Apc mutant mice 
 
The genetically engineered ApcMin mouse was the first mouse strain generated to model 
human intestinal cancer (216). The Min (multiple intestinal neoplasia) mice carry a 
truncating mutation at the position 850 of the Apc gene (217). In contrast to human FAP, 
the Apc mice develop polyps mainly in the small intestine. Heterozygotic ApcMin mice 
typically develop approximately 30 polyps mostly in the small intestine, by 100-120 days of 
age. Several additional Apc mutant strains with slightly varying phenotypes have been 
constructed since using gene knock-out technology. These include Apc 716, 1638 and 
1309 mice strains that carry truncating mutations in the respective codons (218-220). 
Studies based on Apc?716 mice showed that polyp formation is initiated by loss of 
heterozygozity (LOH) of the Apc locus in proliferative cells (219). 
 
Mouse models have been utilized for investigating effects of dietary components on CRC 
risk. Studies based on especially ApcMin mice have provided evidence that several 
bioactive food components may inhibit CRC in genetically predisposed mice while others 
may increase the risk. For example, a 60% calorie-restricted diet was shown to decrease 
the amount of intestinal polyps in ApcMin mice by 60% which supports observations from 
human studies (221). Mechanistically, decreased amount of total energy is recognized to 
reduce cell proliferation and inflammation and increase apoptosis (222).  Similarly, the 
consumption of certain fatty acids such as steraridonic acid (SDA), eicosapentaencic acid 
(EPA) and docosahexaenoic acid (DHA) were shown to reduce tumor number in the small 
intestine of ApcMin mice (223). Consequently, the ratio of n-6 and n-3 fatty acids may 
contribute to CRC risk since low relative ratio results in decreased proinflammatory 
products arising from n-6 fatty acids which slows down cell proliferation and decreases the 
amount of detected tumors (224).  
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When saturated fat content was increased from 3% to 10% and 15% tumor number 
increased 28% and 47% in ApcMin mice, respectively (225). Similarly, feeding high fat and 
low fiber diet was found to increase tumor formation in Apc?716 mice (226) whereas a 
Western-style diet with high fat, low calcium and vitamin D was found to accelerate tumor 
development in Apc1638N mice (227). In line with studies with healthy human populations, 
exercise was found to reduce the number of polyps in the ApcMin mice by 30-40% (228). 
  
Interestingly, natural compounds such as sulforaphane, derived from cruciferous 
vegetables, chafuroside, a derivative in oolong tea, and curcumin, which is a common 
plant phenolic compound, have been reported to cause a significant reduction of intestinal 
tumors in ApcMin mice (229-231). Sulforaphane is known to decrease proliferation and 
induce apoptosis in a variety of mammalian cell lines whereas chafurosid has been shown 
to increase apoptosis, reduce inflammation and protect against free radicals (232, 233). 
Curcumin is believed to act as an antioxidant and anti-inflammatory factor through 
modulation of multiple signaling pathways (234). 
 
MMR deficient mice 
 
Mouse models with disrupted mammalian MutL and MutS homologs have been generated 
to study the effects of MMR defects on cancer predisposition. Analysis of the mouse 
models has revealed that the basic mechanisms of DNA repair are similar in mice and 
human and phenotypes of MMR knockout mice correlate with the DNA repair defects and 
the mutation frequency of the Lynch syndrome patients (235). However, unlike human 
MLH1, MSH2 and MSH6 mutation carriers, heterozygous mice rarely develop early-onset 
tumors (<1 year old) (236). Knock-out mice with homozygous mutations are predisposed 
to cancer with a tumor spectrum that includes gastrointestinal cancers, but unlike LS 
patients, majority of mice die prematurely due to T-cell lymphoma which is the 
predominant malignancy in mice (236). Differences in phenotype and tumor incidence 
between mice and human are likely explained by the smaller size and shorter life span of 
mice (237). Consequently, somatic loss of the wildtype allele and subsequent 
tumorigenesis are more likely to happen during a longer period of time in humans whereas 
tumorigenesis in mice is more unlikely. Differences in organ manifestation is suggested to 
be caused by the absence of many coding mononucleotide repeats (cMNR) in the mouse 
genes which makes them less vulnerable to MSI effects (237). 
 
Heterozygous Mlh1+/- mice have been shown to have reduced longevity caused by 
lymphomas and to a lesser extent develop tumors in the intestinal tract (238). Of 
heterozygous Mlh1+/- mice half have been reported to die by the age of 18 months and 
approximately one third develop tumors in the intestine and other organs. Knock-out mice 
with homozygous mutations develop a more aggressive cancer predisposition phenotype 
including a spectrum of different types of tumors including intestinal cancer. MMR 
deficiency in Mlh1-/- mice causes a significant reduction in lifespan and a severe cancer 
predisposition phenotype including development of T-cell lymphomas by 6 to 8 months of 
age and development of small intestinal adenomas and carcinomas and skin cancer 
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slightly later by 6 to 12 months of age (239, 240). Similarly, rare human patients with 
biallelic mutations in MLH1, MSH2 and MSH6 are prone to hematological malignancies 
(241). Tumors arising in mice with homozygous mutations display MSI in both mono- and 
dinucleotide repeats at high frequency similar to human mutation carriers (242). Moreover, 
loss of Msh2 in homozygous Msh2-/- mice causes MMR deficiency with a severe mutator 
phenotype (243). Similar to Mlh1-/- mice, tumor spectrum of these mice includes T-cell 
lymphomas and intestinal adenomas and carcinomas with MSI phenotype.  
 
Msh6-/- mice have a longer lifespan (up to 18 months) and develop a similar cancer 
predisposition phenotype to Mlh1-/- and Msh2-/- mice with a delayed age of onset and lack 
of mononucleotide repeat instability and low level of dinucleotide instability (244). Similar 
to MSH6 human mutation carriers Msh6-/- mice are predisposed to developing endometrial 
cancer (245, 246). Pms2-/- mice have a delayed age of onset with predisposition to 
hematological malignancies but not to gastrointestinal tumors (247). In Pms2-/- mice MSI 
occurs in both mono- and dinucleotide repeats and compared to other MMR-knockout 
mice increased frequency of frameshift mutations is observed (248, 249). The differences 
in the phenotype and tumor spectrum are most likely to be caused by the milder mutator 
phenotype resulting from a partial repair defect caused by Pms2 deficiency. This is in line 
with observations from human PMS2 mutation carriers that have an overall lower risk for 
cancer and a later age of onset (131). 
 
To develop mouse models that more accurately mimic the cancer phenotype and tumor 
spectrum of LS patients, MMR knock-out mice have been intercrossed with mice carrying 
additional mutations in tumor suppressor or oncogenes frequently mutated in human CRC 
such as APC, TP53 and KRAS (250). For example, the combination of homozygous 
mutations in MMR genes and heterozygous Apc mutations accelerates the tumor 
development to the intestinal tract. However, these mice display MMR deficiency in all 
tissue types in contrast to LS patients. More recently, mice with conditional disruption of 
Msh2 were generated using mice that express transgenic intestine specific Villin-Cre 
recombinase and LoxP sites which together induce the deletion of exon 12 and MMR 
deficiency limited to the intestinal epithelium (251). In this model tumorigenesis was 
restricted to the intestinal tract and mice typically developed 1-2 intestinal carcinomas 
pathologically identical to LS tumors during the first year of their life and lacked the 
lymphoma phenotype completely. 
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AIMS OF THE STUDY 
 
Both lifestyle and diet together with genetic and epigenetic factors are known to contribute 
the increased risk for CRC but the molecular mechanisms that initiate tumor development 
remain unknown. The main aims of this investigation were to 1) study the effects of 
Western-style diet on normal appearing colonic mucosa and to identify molecular 
mechanisms underlying the WD-induced risk for CRC, and 2) to define the timing of 
molecular changes occurring during transformation from normal colonic mucosa to pre-
cancerous and cancerous lesions from patients with hereditary CRC. 
 
More specific aims were: 
 
? To study whether and how Western-style diet and genetic predisposition may 
separately or in interaction effect the proteome of histologically normal colonic 
mucosa in mouse models for Lynch syndrome and sporadic CRC (I-II).  
 
? To define how CpG island methylation changes throughout the adenoma-
carcinoma progression sequence in relation to MMR protein expression in 
human LS mutation carriers (III). 
 
? To investigate possible carcinogenic field defects in the normal appearing tissue 
(I-III). 
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METHODS 
 
MOUSE MODELS AND DIETS (I-II) 
 
All mice included in this study were bred and treated according to the study protocol 
approved by the National Animal Experiment Board of Finland (ESLH-2008-06502/Ym-23). 
Mlh1+/+ and Mlh1+/- mice with C57BL/6 background (240) were randomly assigned into two 
dietary groups at the age of 5 weeks. Study I included mice with both genotypes whereas 
study II focused on wild-type Mlh1+/+ mice only (Fig. 5). Groups contained even numbers of 
females and males. Preceding the division to diet groups at 5 weeks (5w) of age, mice 
from each genotype group were sampled forming a baseline for the experiment (Fig. 5). 
The remaining mice were assigned to different diet groups and fed ad libitum with AIN-93G 
(AIN) control diet (252) or Western-style diet (WD) (Harlan Teklad, Madison, WI) with 12 
hours light/dark circle (Fig. 5). AIN-93G control diet is a semisynthetic diet designed to 
meet the nutritional requirements of growing rodents whereas WD is a modified AIN-93G 
diet designed to reflect the nutritional content of average human Western-style diet (Table 
2). Of total energy content fats comprise 39% and 17% and carbohydrates 42% and 64% 
in WD and AIN-93G, respectively. 
 
Before division to diet groups genotypes were confirmed according to NCI – Mouse 
Repository protocol (mouse.ncifcrf.gov) using genomic DNA extracted from earmarks 
(DNeasy Blood & Tissue Kit, Qiagen, Germany). Briefly, PCR reaction contained primers 
M001 (5'-TGT CAA TAG GCT GCC CTA GG -3') (0.33?M), M002 (5'-TGG AAG GAT TGG 
AGC TAC GG -3') (0.33?M), and M003 (5'-TTT TCA GTG CAG CCT ATG CTC -3') 
(0.3?M). Amplicons M001 – M002 (500bp) and M001 – M003 (350bp) correspond to non-
functional and functional Mlh1 allele, respectively. 
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Table 2. Composition of the experimental diets. 
    
AIN-
93G1    
[g/kg]2 
WD1    
[g/kg]2 Compound 
Protein [% of energy] 19 19 
Casein 200 232 
L-cystine 3.0 3.0 
Carbohydrates [% of 
energy] 64 42 
Corn starch 392 305 
Malodextrin 132 95 
Sucrose 100 116 
Cellulose 50 20 
Fat [% of energy] 17 39 
Anhydrous milk fat  -  133 
Canola oil  -  55 
Sunflower oil  -  12 
Soybean oil 70  -  
kcal/g 3.8 4.6 
Calcium Phosphate 5.0 1.7 
Folic acid 0.2 0.0003 
Vitamin D3 (500 000 IU/g) 0.2 0.0003 
1Irradiated for study II 
2If not stated otherwise 
 
Mice were sacrificed and sampled at the age of 12, 18 and 21 months. The colon was 
removed, opened, rinsed with 0.9% sodium chloride solution, inspected for neoplasia 
under a microscope and divided horizontally into pieces. All neoplastic/hyperplastic lesions 
were collected into formalin fixed paraffin (FFPE) blocks and verified at Finnish Center for 
Laboratory Animal Pathology, University of Helsinki. Proximal colonic mucosa (6x4 mm) 
for DNA, mRNA, protein and metabolite studies was separated from the underlying 
submucosa and muscular layer under a dissecting microscope. Since LS tumors have a 
tendency to arise in the proximal part of the colon, the present study concentrates on 
expression changes in the respective part of the mouse colon. Colonic mucosa for protein 
extractions was rinsed with 10 mM Tris and 5mM magnesium acetate solution (pH 8.5) 
(Sigma-Aldrich, Germany), snap frozen and stored at -80°C. Samples for RNA extraction 
were stored in RNAlater (Qiagen) at -80°C.  
 
A more detailed description of the methodology used in this study including specifications 
of primers, probes, reaction conditions and MS parameters can be found in the original 
publications (I-III). A summary of the methods used in this study is presented in Table 3. 
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Table 3. Summary of methods. 
Methods Publications 
DNA, RNA and protein extractions and quantification I-III 
PCR-based genotyping I-II 
Two-dimensional difference gel electrophoresis (2D DIGE) I-II 
Matrix-assisted laser desorption ionization coupled with mass spectrometry (MALDI-
MS) I-II 
Liquid chromatography coupled with mass spectrometry (LC-MS) II 
Quadropole time of flight mass spectrometry (Q-TOF-MS) II 
Ingenuity Pathway Analysis (IPA) I-II 
Extraction of bile acids from tissue samples II 
Ultra performance liquid chromatography (UPLC) II 
Immunohistochemistry (IHC) II-III 
DNA bisulfite conversion III 
Bisulfite sequencing III 
Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) III 
Microsatellite instability (MSI) analysis  III 
RNA profiling by microarray III 
Statistical analyses I-III 
 
 
QUANTITATIVE PROTEOMIC ANALYSIS (I-II) 
 
2D Difference gel electrophoresis (2D-DIGE) 
 
2D difference gel electrophoresis (2D DIGE) was used to study proteomic changes in 
colonic mucosa (Fig. 6). All reagents and equipment used for this purpose were provided 
by GE Healthcare (UK). Half of the samples of each experimental group were labeled with 
1-(5-carboxypentyl)-1'-propylindocarbocyanine halide (Cy3) N-hydroxy-succinimidyl ester 
and the other half with 1-(5-carboxypentyl)-1'-methylindodi-carbocyanine halide (Cy5) N-
hydroxysuccinimidyl ester fluorescent dyes (400 pmol of dye for 50 ?g of sample) 
according to manufacturer’s instructions. An internal standard was created by pooling 
25?g of each protein sample and labeled with 3-(4-carboxymethyl)-phenylmethyl-3’-
ethyloxacarbocyanine halide (Cy2) N-hydroxysuccinimidyl ester. Proteins were separated 
according to their isoelectric point using 24cm long immobilized pH 3-11 non-linear 
gradient (IPG) strips and the Ettan IPGphor II unit. Equal amount (50?g) of internal 
standard labeled with Cy2 was combined with Cy3 and Cy5 labeled samples and loaded 
into the IPG strips using cup-loading method according to manufacturer’s instructions. 
After isoelectric focusing IPG strips were equilibrated with 1% dithiothreitol (DTT) and 
2.5% iodoacetamide. Separation of proteins according to their molecular mass was carried 
out by transferring the equilibrated IPG strips to 12.5% SDS-PAGE gels and running with 
constant power of 15 W per gel. Images were acquired by Typhoon 9400/Trio scanner with 
excitation/emission values 480/530 nm, 520/590 nm and 620/680 nm for Cy2, Cy3 and 
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Cy5, respectively. Maximum intensities between channels were optimized to differ less 
than 20 - 30%. Data analysis was performed using DeCyder 2D 7.0.  
 
 
 
Fig. 6. Overview of the 2D DIGE method. Modified from 2-D Electrophoresis: Principles 
and Methods Handbook, GE Healthcare. 
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Protein identification and validation 
 
Scanned 2D DIGE gels were silver-stained using PlusOne Silver staining kit (GE 
Healthcare). Proteins of interest were excised and in-gel digested by trypsin (Trypsin gold, 
Promega, Sweden). MALDI-MS and MALDI-MS/MS analyses were performed with 
Autoflex III and UltraFlexTremeTM (Bruker Daltonics, Germany) for studies I and II, 
respectively. Calibration was externally performed with peptide calibration standard 
(Bruker Daltonics). MALDI-MS and MS/MS spectra were acquired by accumulation of 
5000 - 7000 laser shots and 10 000 – 20 000 laser shots, respectively. Processed spectra 
were searched against UniProt/SwissProt database (www.uniprot.org) with taxon: Mus 
musculus using Mascot server (Matrix Science, www.matrixscience.com) and FlexAnalysis 
and BioTools software (Bruker Daltonics). 
 
In study II, results obtained with 2D DIGE were validated by analyzing pools of total protein 
extracts with quantitative liquid chromatography tandem mass spectrometry (LC-MS). 
Pools were created by combining 10 ?g of total protein extract from individual mice of each 
experimental group. Of created protein pools 10 ?g was used for digestion that was carried 
out using a modified Filter Aided Sample Prep (FASP) protocol (253). Triplicates of 
digested proteins (200ng) were injected for LC-MS analysis. Relative quantification 
between samples using precursor ion intensities was performed with TransOmicsTM 
Informatics for Proteomics software (Nonlinear Dynamics, Waters) and ProteinLynx Global 
Server (PLGS V3.0). Chromatograms were aligned by the TransOmicsTM software using 
the default settings. Alignment scores ? 70% were selected for further analysis. Database 
searches were carried out against UniProtKB-SwissProt (release 2014_04, taxon: Mus 
musculus, 32538 entries). 
 
PATHWAY ANALYSIS (I-II) 
 
In study I, gene ontology (GO) annotations were analyzed with the Panther Protein 
Classification System (http://www.pantherdb.org/) to distinguish significantly enriched 
functional annotations from the proteomics data. The corresponding GO terms were used 
to classify protein functions. GO biological process (GO BP) criteria were further applied to 
analyze the enriched networks and to maximize connectivity between all input genes in a 
given ontology class. In study II, proteomics data were analyzed with Ingenuity Pathway 
Analysis (IPA) (Qiagen) to identify enriched pathways and upstream regulators. Heat maps 
of significant z-scores were generated for upstream regulators, diseases and functions and 
classical pathways using R version 3.2.0 (2015-04-16) and NMF package. 
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HISTOLOGICAL ANALYSIS OF COLONIC CRYPTS (II) 
 
The length was measured and the number of cells was counted from five colon crypts per 
mouse in blinded manner using hematoxylin and eosin (HE) stained proximal colonic 
tissue sections. Proliferation index (Ki67 index) was studied by immunohistochemistry 
(Anti-Ki67, 1:1000, ab15580, Abcam, UK). Slides were scanned with Pannoramic 250 
Flash II (3D Histech, Hungary); visualization and analysis was performed with CaseViever 
(3D Histech). Proliferation index was calculated by dividing the number of Ki67 positive 
cells with the number of total cells within a crypt. 
 
EXTRACTION AND QUANTIFICATION OF BILE ACIDS (II) 
 
Bile acids were extracted from proximal colon mucosa in ethanol as described (254). 
Briefly, lyophylizated samples were homogenized in TissueLyser (Qiagen). Nordeoxycholic 
acid (NDCA) (Steraloids, USA) was added (0.5 ?g) to the samples prior the ethanol 
extraction and used as an internal standard to monitor sample quality and normalization. 
Ultra performance liquid chromatography (UPLC) (Waters, Milford MA, USA) was utilized 
to measure the concertation of BAs in colonic tissue. UPLC system was interfaced with 
Waters Synapt G2 HDMS mass spectrometer (Waters, Milford MA, USA). Ionization was 
performed using an electrospray ionization (ESI) source. The ionization parameters were 
optimized with the internal standard, 23-nordeoxycholic acid (NDCA). The bile acids were 
identified by their m/z ratio and retention time and by running BA standards (NDCA, 
deoxycholic acid (DCA), cholic acid (CA), hyodeoxycholic acid (HDCA), chenodeoxycholic 
acid (CDCA), ursodeoxycholic acid (UDCA), lithocholic acid (LCA), isoLCA, alpha-
muricholic acid (?MCA), ?MCA, ?MCA, ?-tauromuricholic acid (?TMCA), ?TMCA 
Steraloids, USA). The chromatograms and mass spectra were analyzed with Waters 
MassLynx™ Software (Waters, Milford MA, USA). 
 
PATIENT SAMPLES (III) 
 
Patient samples included in this study originated from the nation-wide Hereditary 
Colorectal Cancer Registry of Finland. Colorectal fresh frozen biopsies together with blood 
samples were gathered from Finnish LS mutation carriers during colonoscopy screenings 
and colectomies performed at Helsinki University Central Hospital and Jyväskylä Central 
Hospital during 10/2011–5/2013. Normal mucosa biopsies were collected from 1–4 distinct 
colonic regions in addition to biopsies from hyperplastic polyps, adenomas and 
carcinomas (Table 1/III). Half of each tumor was snap frozen in liquid nitrogen for 
subsequent DNA analysis while the remaining other half was submitted to histological 
analysis. This series formed the so called prospective series. DNA was extracted from the 
fresh frozen tissue biopsies using AllPrep DNA/RNA Mini Kit (Qiagen). The Institutional 
Ethics Board of Central Finland Health Care District approved the collection of biopsies 
during surveillance (K-S shp Dnro 10U/2011). 
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All previously diagnosed adenomas and carcinomas of LS patients included in the 
prospective series were gathered forming the retrospective series. Forty-three patients 
from the prospective series contributed to the archival specimens. The retrospective series 
consisted of colorectal tumors and, when available, matching normal mucosa (Table 1/III). 
The histology of tumors was verified by a gastrointestinal pathologist. Carcinoma sections 
used for DNA extraction contained 50% of tumor epithelium on average (range 30–80%). 
DNA was extracted from representative FFPE tissue sections according to the method of 
Isola et al. (255). The National Authority for Medicolegal Affairs (Dnro 1272/04/044/07) 
approved the collection of archival specimens.  
 
MMR PROTEIN EXPRESSION (III) 
 
Immunohistochemistry was used to measure MMR protein expression of the gene mutated 
in the germline in all neoplastic lesions collected from LS mutation carriers. Four-
micrometer sections were cut from FFPE tissues and processed for 
immunohistochemistry. Specimens were immunohistochemically stained with MLH1 (1:50, 
clone ES05, Dako North America, Carpinteria, CA), MSH2 (1:1000, clone G219-1129, BD 
Pharmingen, San Diego, CA), MSH6 (1:100, clone EP49, AC00-47, Epitomics, 
Burlingame, CA), and PMS2 (1:1000, clone EPR3947, Abcam, UK) antibodies. MLH1, 
MSH2, MSH6 were visualized with Ventana BenchMark XT immunostainer using OptiView 
detection system and PMS2 using OptiView + Amplification detection system (Ventana 
Medical Systems, Tucson, AZ). Negative cancer cell immunostaining was interpreted to 
indicate inactivation of the respective MMR gene. 
 
MICROSATELLITE INSTABILITY (MSI) ANALYSIS (III) 
 
Tumor specimens were investigated for MSI using the mononucleotide repeat markers 
BAT25 and BAT26, which are sensitive and specific indicators of the MSI-high phenotype 
(256, 257). Tumors with unstable BAT25 or BAT26 were classified as MSI, whereas those 
with normal BAT25 and BAT26 were considered microsatellite-stable (MSS). 
 
METHYLATION ANALYSIS (III) 
 
All methylation analyses were conducted by methylation-specific multiplex ligation-
dependent probe amplification (MS-MLPA) method, the basic principle of which was 
described by Nygren et al. (258). In brief, the probes contain a recognition sequence 
(GCGC) for the methylation-sensitive endonuclease HhaI (Promega, Wisconsin, USA). 
Methylated CpG dinucleotides within a restriction site are not recognized by the HhaI 
enzyme. Probes that bind methylated sequences are therefore protected and amplified in 
PCR which generates a signal peak. All MS-MLPA reactions and analyses were performed 
according to the manufacturer’s instructions (259) using 200–600 ng of DNA. The PCR 
products were separated by capillary electrophoresis (ABI 3730 Automatic DNA 
Sequencer, Applied Biosystems, Carlsbad, CA, USA) and analyzed by GeneMapper4.0 
genotyping software (Applied Biosystems).  
  METHODS 
44 
 
The methylation dosage ratio (Dm) was calculated for each normal mucosa and tumor 
sample as previously described (260). The Dm value of 0.15 or above (corresponding to 
15% of methylated DNA) was treated as the conservative technical threshold for 
methylation detection (258). Since the baseline level for methylation in normal tissue may 
vary between probes, normal mucosa specimens were used to determine thresholds for 
hypermethylation in tumor tissues. 
 
To study promoter methylation as a putative second hit, the methylation status of MMR 
genes was analyzed by SALSA MLPA probemix ME011 (MRC Holland, Amsterdam, The 
Netherlands). Analyzed MLH1 promoter regions corresponded to regions A, B and C as 
described in Deng et al. (261). Promoter methylation of eight CIMP marker genes 
(CACNA1G, IGF2, NEUROG1, RUNX3, SOCS1, CDKN2A, MLH1 and CRABP1) was 
studied by SALSA MLPA probemix ME042 (MRC Holland, Amsterdam, The Netherlands). 
Two alternative marker panels, proposed by Weisenberger et al. and Ogino et al. (See 
chapter: CpG island methylator phenotype), were used to classify tumors as CIMP-positive 
or non-CIMP depending on how many markers were found to be hypermethylated (3/5, 5/8 
or 6/8) (84, 90).  
 
A custom MS-MLPA assay was designed to study methylation of promoter regions of 
seven candidate genes (DKK1, SFRP1, SFRP2, SFRP5, CDH1, HOXD1 and SLC5A8) 
previously associated with early colon oncogenesis (7). The methylation profile of CpG 
islands was investigated by bisulfite sequencing DNA from cancer cell lines (HCT15, 
HCT116, RKO, SW480, T84, AN3CA and HEC59) and normal tissue (Genomic DNA – 
Human Adult Normal Tissue: Uterus and Colon, from a single donor, Biochain, CA, USA). 
Bisulfite conversion of DNA (600ng) was carried out using EZ DNA Methylation-DirectTM 
Kit (Zymo Research, Orange, CA, USA). The promoter areas under investigation were 
amplified and sequenced from bisulfite-modified DNA with methylation-unbiased primers. 
Custom MS-MLPA probes were subsequently designed to target representative 
methylation-sensitive restriction enzyme HhaI restriction sites (GCGC). To complete the 
MS-MLPA assay, Salsa MLPA P300-A2 Human DNA Reference-2 (MRC Holland, 
Amsterdam, The Netherlands) was added to the custom designed MS-MLPA probe mix. 
The custom assay was optimized against bisulfite sequencing as described (262).  
 
 
To determine the sensitivity of the MS-MLPA method a gradient with decreasing amount 
(100%, 50%, 25%, 15%, 5%, 0%) of methylated control DNA diluted into a solution of 
unmethylated control DNA (Human Methylated & Non-methylated DNA Set, Zymo 
Research, Orange, CA, USA) was analyzed. 
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DEMETHYLATION TREATMENT AND RNA EXPRESSION PROFILING OF CELL LINES 
(III) 
 
Cancer cell lines were treated with demethylation agents according to Derks et al. (263). 
RNA profiling of treated and untreated cell lines was performed using Affymetrix Human 
Genome U133 Plus 2.0 GeneChip® microarrays (Affymetrix, Santa Clara, CA). Samples 
were amplified, labeled and hybridized as described (264). Microarray data analysis was 
performed by GeneSpring GX software, version 12 (Agilent Technologies, Santa Clara, 
CA) using RMA normalization. Statistically significant gene expression changes were 
identified by moderated t test combined with the Benjamini and Hochberg correction for 
multiple testing and by using filters based on p-value cut-off 0.05 and fold change cut-off 
+/-1.5. 
 
STATISTICAL ANALYSES (I-III) 
 
Statistical significance of observed changes between experimental groups in mouse 
weight (I-II), amount of tumors (I-II), length of colon crypts (II), number of cells (II), 
proliferation index (II) and bile acids concentrations (II) were tested with Mann-Whitney U 
test. The amount of tumors in study II follow negative binomial distribution which was 
utilized to analyze the effect of age and diet on tumor development (265). Calculations 
were performed in R version 3.2.0 (2015-04-16). 
 
Protein expression changes detected by 2D-DIGE (I-II) were analyzed by DeCyder 2D 
version 7.0 (GE Healthcare). Statistical significance of expression changes observed 
between the experimental groups were tested with the Student’s t-test with significance 
threshold p ? 0.01. Proteins with p ? 0.01 were considered as proteins of interest (POI). 
Mice fed with WD were compared with control diet groups (AIN) in order to detect diet 
effects at different time points. Combined effect of diet and aging was studied by 
comparing different time points. Hierarchical clustering and principal component analysis 
(PCA) were performed on filtered protein set using DeCyder 2D Extended Data Analysis 
for normalized protein abundances in order to demonstrate differences between 
experimental groups. Statistical data was utilized to detect the protein spots that 
contributed to the highest differences between experimental groups. These protein spots 
were then selected and processed for protein identification (Fig. 5). 
 
 
For LC-MS proteomic analysis (II) the between-subject ANOVA design scheme of 
TransOmicsTM software was utilized. The thresholds to accept protein leads based on 
differential intensities between experimental groups were: absolute fold-change ? 2 
computed from averaged and normalized protein intensities, and p value ? 0.05 for 
ANOVA in all comparisons. 
 
 
  METHODS 
46 
 
Statistical analysis of methylation data (III) was performed using the SPSS software, 
version 20.0 (IBM SPSS Inc. Chicago, IL, USA). Frequency of methylated target sites in 
each type of tissue specimen was calculated separately for each gene using the probe-
specific threshold values. Fisher’s exact test was used to calculate 2-sided p values for 
each pairwise comparison and Bonferroni correction was used to adjust p values for 
multiple comparisons. Pearson’s correlation was used to study the association between 
age at biopsy and normal colonic mucosa methylation in the prospective series.  Statistical 
significance of methylation changes detected in normal colonic mucosa (III) between study 
groups was tested by One-way ANOVA and Tukey’s post hoc test was used for pairwise 
comparisons. Alternatively, the non-parametric test Kruskal-Wallis (k samples, pairwise 
comparisons) was utilized for series that were not normally distributed. Homogeneity of 
variances was tested by Levene’s test and normality by Shapiro-Wilk test. P values ? 0.05 
were considered significant. 
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RESULTS AND DISCUSSION 
 
 
I. EFFECTS OF WESTERN-STYLE DIET ON NORMAL COLONIC MUCOSA OF MOUSE 
MODELS FOR LS AND SPORADIC CRC (I-II) 
 
Western diet increases weight and induces neoplastic changes in the colon 
 
Overall in both studies I and II, mice fed with WD gained significantly more weight when 
compared to the control diet group (Fig. 6). Weight gain was defined as the increase in 
weight between the experiment start point (5 weeks) and different time points of 
experiment (12m, 18m and 21m). No significant differences were observed in average 
weight between experimental groups at the start point of the experiment. Experimental 
groups consisted of equal numbers of female and male mice. In both studies male mice 
tended to gain more weight compared to females. When sexes were combined, the 
average weight gain was 15.13g ± 4.85 and 26.97g ± 7.77 in study I for mice fed with AIN 
and WD, respectively, indicating significant effect of diet (p=0. 0005). No differences in 
weight gain was observed between the two different genotypes (Mlh1+/+ and Mlh1+/-). 
Study II focused on wild-type Mlh1+/+ mice only. In study II, the average weight gain was 
20.8g ±5.2 and 24.2g ±6.0 (12m); 23.1g ±6.1 and 29.6g ±7.7 (18m) and 24.3g ±6.0 and 
29.0g ± 6.5 (21m) for mice fed with AIN and WD, respectively (Fig. 7). In study II, the 
differences in average weight and weight gain for mice were smaller between the two 
different diet groups. This was most probably caused by the different environments of the 
two animal facilities utilized in the two studies. In addition, the fact that irradiated diet was 
required for study II had most likely significant effects on the diversity of gut microbiota, 
which was not addressed in this study. Interestingly in study II, mice fed with AIN 
continued to gain weight until 21 months of age, while WD fed mice started to lose weight 
after 18 months most probably due to deterioration of health. 
 
All macroscopic findings were histologically verified by an animal pathologist. In study I, 2 
colonic hyperplasias, 3 adenomas and 1 adenocarcinoma were observed among the 29 
mice at 12m (Fig. 8). Although differences remained statistically non-significant due to low 
number of mice, five out of the six tumors were detected in mice fed with WD including 
both genotypes, indicating that WD increases the risk of colonic tumors also in mice with 
no genetic predisposition. The single exception, a mouse with hyperplasia, was a carrier of 
the Mlh1 mutation. In study II, 7 adenocarcinomas, 1 adenoma and 12 hyperplasias were 
detected in 77 mice included in the study (Fig. 8). Of all tumors in study II, 16 out of 20 
were detected in mice fed with WD when compared to AIN (p=0.006). Both aging and diet 
increased significantly the likelihood of developing a tumor (Fig. 8). Coefficients for aging 
and WD were 1.91 (p=0.012) and 1.41 (p=0.012), respectively. Compared to study I, mice 
developed less colonic lesions and only three tumors were detected at 12m, all of them in 
WD fed mice. The majority of tumors were detected at 18m and 21m. Overall, in studies I-
II 8 colonic adenocarcinomas, 4 adenomas and 14 hyperplasias were detected altogether. 
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Of all colonic lesions 21 out of 26 were detected in mice fed with WD indicating that WD 
feeding promotes the development of colonic tumors (p=0.001).  
 
 
 
Fig.7. Increased average weight gain in mice fed with Western diet. Statistical significance 
(*p ? 0.05) of pairwise comparisons were tested by Mann-Whitney U test. Error bars 
represent standard error of the mean. 
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Fig.8. Colonic tumor number in different experimental groups in studies I-II. Tumor 
histologies are specified as hyperplasia (HP), adenoma (AD) or carcinoma (CRC). 
 
Our observations are in line with Newmark et al. who reported for the first time that long-
term feeding of WD by itself was able to induce tumors in the colon of wild-type C57Bl/6 
mice without any other chemical carcinogen exposure or targeted mutations (266, 267). 
Similarly, they reported increased body weight after one month of WD feeding which 
gradually increased during the study. The nutritional content of the Western-style diet used 
by Newmark et al. was comparable to the diet used in our investigation. However, 
Newmark et al. used corn oil as a fat source, whereas our modification of the diet 
contained substantially increased amount of saturated fat from anhydrous milk, which may 
affect tumor susceptibility. 
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Significant changes in the colon proteome caused by aging and diet 
 
Increased number of tumors observed in mice fed with WD is most probably caused by 
accumulation of alterations in the colonic epithelium which precede tumor development 
and act as drivers for colonic tumorigenesis. To determine proteomic alterations in normal 
appearing colonic mucosa associated with WD and aging, colonic proteomes of mice were 
studied at different time points (5w, 12m, 18m and 21m). Proteome differences between 
the experimental groups were studied with 2D difference gel electrophoresis (2D DIGE) 
and analyzed with DeCyder2D Software 7.0. In studies I and II, 1383 and 1974 
differentially expressed proteins were detected out of which 394 and 368, respectively, 
were regarded as statistically significant (p ? 0.01). In both studies, most protein 
expression changes were detected between the experimental start point and the three 
different time points, indicating that aging had the most prominent effect on the overall 
protein expression.  
 
In study I, based on the significant protein expression changes detected by 2D DIGE the 
5-week-old mice clustered separately from the other experimental groups (Fig. 9). The two 
diet groups containing mice with both genotypes clustered separately according to diet, 
resulting in two additional clusters. This indicates that overall proteomes were more 
consistently changed by diet than by Mlh1 genotype. Protein expression changes often 
showed similar trends in the wild-type Mlh1+/+ and genetically predisposed Mlh1+/- mice. 
However, most significant expression changes were detected in Mlh1 mutation carriers fed 
with WD when compared to AIN control diet groups whereas the proteomes of wildtype 
Mlh1+/+ mice expressed more variability. Less statistically significant protein expression 
changes were observed in Mlh1+/+ mice in association with diet. This may indicate that 
Mlh1 deficiency contributes to the overall expression changes but the robust effect of diet 
per se on proteomes may have impeded the recognition of possible genotype effects. No 
significant genotype effects were observed in proteomes between Mlh1+/+ and Mlh1+/- mice 
within the same diet group. However, further studies are required to elucidate the 
interaction of Mlh1+/- genotype and diet. 
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Fig. 9. Hierarchical clustering of experimental groups in study I based on average values 
of significant protein expression changes detected by 2D DIGE. Color scale represents 
logarithmic values of expression fold changes. Proteomes were more consistently 
changed by diet and aging than by genotype. 
 
Since dietary habits are known to predispose to sporadic CRC and the effect of WD on 
colonic proteome was evident in study I, study II focused on wild-type Mlh1+/+ mice only. In 
order to further investigate effects of WD and aging on the colonic proteome and CRC risk, 
extended number of mice and two additional time points (18m and 21m) were analyzed by 
2D DIGE (Fig. 5). Principal component analysis (PCA) based on 2D DIGE proteomic data 
was utilized to demonstrate differences between experimental groups (Fig. 10A). Similar to 
study I, colonic proteomes of mice at experimental start point (5w) differed the most from 
other experimental groups whereas WD fed mice diverged from AIN fed mice over time 
due to accumulation of protein expression changes caused by diet (Fig. 10A). Principal 
component (PC) 1 mainly associated with diet and described up to 26% variability between 
individuals, while PC2 described additional 11% of variability and associated mainly with 
age. Interestingly, in diet group comparisons most of significant protein expression 
changes were detected at 12m between WD and AIN control diet group. Moreover, 
proteomes of mice at 18 months did not differ significantly from proteomes of mice at 21 
months among the same diet groups (Fig. 10A). Therefore, validation of results and 
downstream analysis focused on differences detected at 12 and 18 months. Since 
tumorigenesis is a multistep process, we reasoned that accumulation of alterations that 
occurred at earlier time points may have predisposed to colonic tumorigenesis at later 
stages which was observed as increased tumor number in 21m WD mice. 
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Fig. 10. PCA based on the expression profiles of 96 proteins identified by 2D DIGE (study 
II). A. PCA with colored clusters of experimental groups. Each dot represents the protein 
expression profile of an individual mouse. Protein expression profiles separate 
experimental groups according to diet (PC1) and age (PC2). Arrows indicate a shift in 
protein expression profiles of mice fed with WD and AIN control diet from the mice at 
experiment start point. B. PCA based on the expression of the 96 identified proteins 
indicates the ones that contribute to the highest differences between experimental groups. 
PC1 and PC2 indicate the proteins that show most prominent expression change between 
diet and age group comparisons, respectively. 
 
 
Proteins involved in energy metabolism and cellular toxicity affected by diet 
 
Since most significant protein expression changes in study I were detected between 
Mlh1+/- WD and AIN control diet groups, proteins for identifications were strictly selected 
from these comparisons. Altogether, 18 proteins were successfully identified by peptide 
mass fingerprinting (MALDI-TOF) (Table 4). Many of the detected expression changes 
associated to metabolic processes and neutralization of cell toxicity. Mlh1+/- WD mice 
showed a remarkable 48% (p=0.008) increase in fatty acid-binding protein 2 (FABP2) 
expression when compared to Mlh1+/- AIN control diet group indicating a response to the 
high dietary fat content of WD (20%) compared to AIN (7%). FABP2 is known to bind a 
variety of fatty-acids and elimination of its function in knock-out mice leads to disturbances 
in lipid metabolism and high-fat diet induced fatty liver (268). Similarly, a 24% (p=0.004) 
increase was observed in Mlh1+/- WD mice when compared to Mlh1+/- AIN for medium-
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chain specific acyl-CoA dehydrogenase (ACADM) expression, involved in fat digestion and 
fatty acid oxidation (FAO). Most probably, increased amount of dietary fat shifts cellular 
metabolism to utilize fatty acids as a primary source of energy instead of glucose. 
Comparisons between Mlh1+/+ WD and control diet mice showed similar trends in 
expression, although they were not statistically significant.  
 
Consumption of Western-style diet has been previously associated with increased toxicity 
caused by reactive oxygen species (ROS) in mice (269). Peroxisomal FAO is the main 
metabolic processes responsible for the generation of hydrogen peroxide (H2O2) that 
belongs to ROS. Increased FAO and oxidative phosphorylation, indicated by 14% 
(p=0.005) increase in ATP synthase subunit ? (ATP5A1) in WD fed mice, suggests WD 
feeding to cause metabolic excess of ROS (270). High levels of ROS production may lead 
to induction of apoptosis or necrosis whereas continuous exposure to low levels of ROS 
increases cell proliferation, likely through altered expression of growth factors and 
oncogenes, which can eventually lead to cancer (271). 
 
The cellular response to protect cells from increased reactive oxygen species is to up-
regulate enzymes involved in the production of electron donor NADPH. This maintains a 
reducing atmosphere in the cells that prevents oxidative damage. Elevated cellular 
response against ROS toxicity was indicated in Mlh1+/- WD when compared to Mlh1+/- AIN 
mice by increased expression of transaldolase (TALDO) (16%, p=0.015) and transketolase 
(TKT) (7%, p=0.013) involved in the pentose phosphate pathway (PPP) which generates 
NADPH. Moreover, isocitrate dehydrogenase [NADP] cytoplasmic (IDH1) enzyme, which 
catalyses synthesis of 2-oxoglutarate from isocitrate with simultaneous reduction of one 
NADP+ molecule to NADPH, showed 18% (p=0.001) increased expression in Mlh1+/- WD 
mice when compared to Mlh1+/- AIN. IDH1 has been shown to act as a tumor suppressor 
with an important role in antioxidant cellular processes (272). In addition, a remarkable 
55% (p=0.0005) up-regulation of selenium-binding protein 1 (SELENBP1) was observed in 
Mlh1+/- WD mice when compared to Mlh1+/- AIN. SELENBP1 is thought to play a role in 
selenium-dependent ubiquitination/deubiquitination mediated degradation of proteins and 
to have tumor suppressor function through inhibiting cell proliferation in low concentrations 
of the ROS such as H2O2 (273). In summary, increased production of NADPH in normal 
colonic mucosa of mice fed WD indicates up-regulation of cellular processes fighting 
against toxicity of ROS to prevent oxidative damage. 
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Table 4. Identified proteins by 2D DIGE in study I. 
                
UniProt 
ID 
NCBI 
Gene ID
NCBI 
Gene 
Symbol 
UniProt Protein 
Name 
MW 
(kDa) pI 
Mlh1+/- AIN / Mlh1+/- WD
Av.Ratio 1T-test 
P13634 12346 3Car1 Carbonic anhydrase 1 28,4 6,44 1,94 0,015 
P17563 20341 3Selenbp1 Selenium-binding protein 1 53,1 5,87 1,55 0 
P55050 14079 2,3Fabp2 Fatty acid-binding protein, intestinal  15,1 6,62 1,48 0,008 
P45952 11364 2,3Acadm 
Medium-chain specific 
acyl-CoA 
dehydrogenase, 
mitochondrial 
46,9 8,6 1,24 0,004 
Q91Y97 230163 3Aldob 
Fructose-
bisphosphate aldolase 
B 
39,9 8,52 1,19 0,014 
O88844 15926 2,3Idh1 
Isocitrate 
dehydrogenase 
[NADP] cytoplasmic 
47 6,73 1,18 0,001 
Q8K419 16855 3Lgals4 Galectin-4 (Lactose-binding lectin 4) 36,4 9,13 1,17 0,019 
Q93092 21351 3Taldo1 Transaldolase 37,5 6,57 1,16 0,015 
Q03265 11946 3Atp5a1 ATP synthase subunit alpha, mitochondrial 59,8 9,22 1,14 0,005 
P19001 16669 2,3Krt19 
Keratin, type I 
cytoskeletal 19 44,5 5,28 1,13 0,011 
P40142 21881 2,3Tkt Transketolase 68,3 7,23 1,07 0,013 
P42932 12469 3Cct8 T-complex protein 1 subunit theta 60,1 5,44 -1,09 0,002 
P62259 22627 2,3Ywhae 14-3-3 protein epsilon 29,3 4,63 -1,09 0,014 
P05784 16668 3Krt18 Keratin, type I cytoskeletal 18 47,5 5,22 -1,19 0 
P52480 18746 3Pkm2 Pyruvate kinase isozymes M1/M2  58,4 7,18 -1,3 0,016 
P19324 12406 3Serpinh1 Serpin H1 46,6 8,88 -1,33 0 
P16045 16852 3Lgals1 Galectin-1 15,2 5,32 -1,33 0,001 
P97315 13007 3Csrp1 Cysteine and glycine-rich protein 1 20,6 8,9 -1,59 0,005 
1 T-test was calculated using DeCyder 2D Software     
2 Identified in study II by 2D DIGE     
3 Identified in study II by LC-MS 
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Induced cell proliferation and deregulation of apoptosis pathways  
 
In study II, proteins with significant expression changes between WD and AIN diet groups 
and different time points were chosen for identification by MALDI-MS. Altogether 96 
proteins were successfully identified, out of which 48, 35 and 28 unique proteins showed 
significant difference in expression when comparing mice fed with WD to AIN at 12, 18 and 
21 months, respectively (Table S2 and S3/II). PCA was utilized to identify proteins with 
highest variability between experimental groups in the 2D DIGE dataset (Fig. 10B). The 
proteins with highest variability between experimental groups were: catalase (CAT), 
cytochrome b-c1 complex subunit 1, mitochondrial (UQCRC1), fatty acid binding protein 6 
(FABP6, also known as ileal bile acid binding protein (ILBP)), gelsolin (GSN), 3'-
phosphoadenosine 5'-phosphosulfate synthase 2 (PAPSS2), sulfotransferase family, 
cytosolic 1A, phenol-preferring, member 1 (SULT1A1), sulfotransferase family, cytosolic 
1C, member 2 (SULT1C2) and transgelin (TAGLN). 2D DIGE results were validated by 
LC-MS which is a platform for high-throughput proteome analysis (Table S5/II). Validation 
was performed using triplicates of pooled total protein extracts for each experimental 
group at 12m and 18m. In 2D DIGE, only proteins with significant expression changes 
between experimental groups were selected for identification by MALDI-MS, whereas 
validation by LC-MS was conducted in a high-throughput manner (Fig. 11). A remarkably 
high proportion (68%) of proteins identified by 2D-DIGE were successfully detected with 
LC-MS (Fig. 11). 
 
 
Fig. 11. Comparison of proteins detected by 2D DIGE and LC-MS (II).  
 
The Ingenuity Pathway Analysis (IPA) software for systems biology analysis was utilized to 
identify upstream activators and enriched pathways in the 2D DIGE and LC-MS 
proteomics datasets. In 2D DIGE dataset, activation of peroxisome proliferator-activated 
receptor (PPAR) ?, ? and ? and insulin receptor networks together with inactivation of acyl-
CoA oxidase 1, palmitoyl (ACOX1), mitogen-activated protein kinase kinase kinase kinase 
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4 (MAP4K4) and tumor necrosis factor (TNF) pathways all pointed to increased 
proliferation, deregulation of apoptosis and cell death in the colonic mucosa of 12m and 
18m WD mice in particular (Fig. 12A). Interestingly, pathway analysis of LC-MS proteomic 
data confirmed the changes detected by 2D DIGE in PPAR and ACOX1 pathways and in 
addition indicated inactivation of bile acid metabolism and farnesoid X receptor (FXR, also 
known as NR1H4), the main nuclear receptor for bile acids (274) (Fig. 12B).  
 
Concurrent increase of proliferation and avoidance of apoptosis in normal tissue is the 
most important oncogenic driver event when considering hallmarks of cancer (275). 
Previous studies performed with mice have reported WD to cause colonic 
hyperproliferation and increased risk for neoplasia (276-278). Crypt length and cell number 
of colonic crypts were analyzed to study the morphological effects of increased 
proliferation and decreased apoptosis indicated by the proteomic data. Indeed, colonic 
crypts of 12m and 18m WD mice were 24 ?m (p=3.15e-9) and 24 ?m (p=1.32e-8) longer 
when compared to AIN control diet groups, respectively (Fig. 13 A-B). Similarly, increased 
amount of cells per crypt was observed in WD mice compared to AIN with the highest 
number of cells observed in the crypts of 12m WD mice which indicated that differences in 
crypt length were caused by increased number of cells and not by increased cell size. 
Difference in crypt length and number of cells between diet groups at 21 months was not 
significant. 
 
The intestinal epithelium is renewed due to proliferation at the base of the crypts and 
apoptosis at the crypt surface. Previous studies have demonstrated an increased 
proliferative activity together with concurrent reduction in apoptosis in normal appearing 
colonic mucosa in patients with advanced colorectal adenomas or carcinomas (279, 280). 
The expansion of proliferative zone from the base of the crypts to the upper portion has 
been associated with increased risk for CRC (281, 282). The positive staining of nuclear 
protein Ki67 is associated with cellular proliferation. Here, the proliferation index, defined 
as a ratio between Ki67 positive cells and total cells within the crypt, was observed to be 
40% higher in crypts of 12m WD compared to 12m AIN mice (p = 3.228e-6) (Fig. 13 C-D). 
Control diet did not result in significant changes in proliferation between different time 
points, indicating that significant increase in length of crypts observed between 12m and 
18m AIN mice was mainly due to increased cell size. These results together with the 
proteomic data indicate that increased crypt length in mice fed with WD and association 
with up-regulated cell proliferation in 12m WD mice in particular may act as a driver for 
colonic tumorigenesis. 
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Fig.12. Enriched pathways and upstream activators based on A. 2D DIGE B. LC-MS 
proteomics dataset (II). Ingenuity Pathway Analysis (IPA) based on protein expression 
changes identified by 2D-DIGE and LC-MS revealed activation of pathways involved in 
proliferation and inactivation of pathways involved in apoptosis and bile acid sensing and 
transport when comparing the different diet groups at 12m and 18m. 
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Fig. 13. Analysis of colonic crypt length and proliferation index in different experimental 
groups (II). A. Representative images of hematoxylin and eosin stained colonic crypts from 
different experimental groups (scale 100 ?m). B. Increased crypt length detected in 12m 
and 18m WD mice when compared to control groups. C. Representative images of IHC 
stainings for Ki67 proliferation marker in different experimental groups. D. Extended 
proliferation zone (Ki67 index) in colon crypts of 12m WD mice when compared to control 
diet and to 18m WD mice. **** p < 0.0001. 
 
Altered bile acid transport induced by diet 
 
Our proteomic data indicated increased cellular toxicity due to increased amount of ROS 
(I, II) together with disruption of lipid metabolism (I, II) and bile acid sensing and transport 
(II) in mice fed by WD. In study II, FABP6, a cytosolic transporter of bile acids, showed the 
most prominent difference in expression between diet groups at all time points (Fig. 14). 
Based on individual expression data from 2D DIGE, the expression of FABP6 increased 
significantly in both groups during the first 12 months regardless of the diet. However, a 
remarkably lower expression was consistently detected in mice fed with WD when 
compared to AIN at all time points. The most significant difference in expression between 
diet groups was observed at 12m (-4.52, p = 1.81e-7). Results were confirmed by LC-MS 
(Fig. 14). In LC-MS, organic solute transporter ? subunit (OST?), also known as solute 
carrier family 51, beta subunit (SLC51B) showed a similar expression pattern as FABP6, 
with significant reduction in expression in 12m WD when compared to 12m AIN mice (-
2.16, p = 0.018). OST? is exclusively expressed within the basal membrane of colonic 
epithelial cells and responsible for transport of bile acids into the extracellular space (283).  
 
5w       12m AIN  12m WD  18m AIN 18m WD 5w 
5w 
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Fatty acid binding proteins are small (15 kDa) cytosolic proteins that bind long-chain fatty 
acids and show tissue specificity. Through their ability to control fatty-acid transport and 
metabolism FABPs are proposed to be central regulators of lipid metabolism, inflammation 
and energy homeostasis (284). FABP6, mainly expressed in the intestinal cells of distal 
parts of small intestine and proximal colon, has a high affinity for binding bile acids and is 
essential for the enterohepatic circulation of bile acids (285, 286).  Enhanced fecal 
excretion and disrupted apical-basal transport of bile acids in the intestinal cells of FABP6 
knock-out mice indicates that intracellular transport of bile acids is tightly dependent on 
FABP6 (287). Consequently, binding and transport of bile acids from lumen to portal 
circulation is reduced indicating that colonic tissue of mice fed with WD might have a 
defected intestinal apical-basal bile acid transport similar to Fabp6-/- mice.  
 
 
 
Fig.14. Protein expression of FABP6 measured by 2D DIGE and LC-MS (II). 
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Bile acids are derived from cholesterol in the hepatocytes as a part of enterohepatic 
circulation which is regulated by dietary and hormonal signals. Cholic acid (CA) and 
chenodeoxycholic acid (CDA) are the two most common primary bile acids produced by 
liver. Most of the bile acids are efficiently absorbed in the ileum and proximal colon by the 
apical sodium-dependent bile acid receptor (ASBT; gene symbol SLC10A2) (288). In the 
cytosol, bile acids bind to FABP6 and are exported across the basolateral membrane and 
back into the portal circulation by the heterodimeric transporter OST?-OST? (283). Bile 
acids that escape the absorption in the ileum are transferred into the colon where they are 
deconjugated by colonic microbiota and converted into secondary bile acids.  
 
Cells of the gastrointestinal tract are constantly exposed to high physiologic level of bile 
acids. Consumption of high-fat and high-beef diet is known to result in significantly higher 
excretion of fecal secondary bile acids, mainly deoxycholic acid (DCA) and lithocholic acid 
(LCA) (188). Consequently, exposure to bile acids is most prevalent among individuals 
who have a high dietary fat intake (289). Elevated secretion of bile acids reflects increased 
production of bile acids in the liver needed in order to emulsify the high level of dietary fat. 
Therefore, notable reduction in bile acid transporters observed in the colonic epithelium of 
12m WD mice directed us to address the intracellular bile acid concentrations. Indeed, 
UPLC-MS analysis of separate bile acids revealed a significant decrease in the total 
concentration of bile acids and secondary bile acids DCA (30%) and LCA (36%) in 
particular in the colonic mucosa tissue of 12m WD mice (Fig. 15). No significant 
differences were observed in BA concentrations when comparing diet groups at 18 
months.  
 
Fig. 15. UPLC-MS measurement of bile acid concentrations in colonic mucosa. Statistical 
significance (*p ? 0.05) of pairwise comparisons were tested by Mann-Whitney U test. 
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Even though consumption of high-fat diet, such as WD, is known to result in elevated 
secretion of bile acids in colon lumen, we detected decreased intracellular concentration of 
bile acids in the colonic mucosa tissue. Bile acids are known to act as endogenous ligands 
for their nuclear receptor FXR which directly induces the expression of proteins, such as 
FABP6, involved in bile acid binding and transport (274). Consequently, reduction in 
intracellular bile acid ligands observed in 12m WD mice most probably causes decreased 
activity of FXR, which was predicted by pathway analysis (Fig. 12B). Decreased activity of 
FXR, followed by down-regulation of FABP6 and other bile acid transporters such as 
OST?, may cause further accumulation of bile acids in the colon lumen and increased 
toxicity on the luminal side of the epithelium. 
 
Bile acids are implicated to be important in the etiology of cancer of the gastrointestinal 
tract, including cancer of the esophagus, stomach, small intestine, liver, biliary tract, 
pancreas and colorectum (290). Moreover, previous epidemiologic studies have reported 
increased fecal bile acid concentrations in populations with a high CRC incidence (291). 
Based on previous studies, secondary bile acids DCA and LCA in particular appear to be 
correlated with increased incidence of CRC (292). However, previous studies on bile acids 
and CRC have concentrated on quantifying fecal bile acids whereas this study is to our 
knowledge the first to address the intracellular concentrations in association with diet.  
 
Bile acids are likely to be related to carcinogenesis since they are known to induce ROS in 
the colonic epithelium (189) which is in line with our proteomic data that suggested 
increased oxidative stress in mice fed with WD. Frequently repeated long-term exposure to 
high concentration of bile acids can cause cells to acquire mutations and retain unrepaired 
DNA damage that may offer growth advantage and resistance to apoptosis. Such 
apoptosis-resistant cells may clonally expand due to natural selection and give rise to 
altered subpopulations which can eventually lead to tumor development. Several 
mechanistic studies have shown increased resistance to DCA-induced apoptosis in 
“normal” colonic epithelial cells from CRC patients (293-295). Moreover, increased bile 
acid levels have been shown to induce cell proliferation (296). Consistent with previous 
studies, our data implicated concurrent increase of proliferation and decreased apoptotic 
processes in the colonic epithelium exposed to WD. On the contrary, we observed 
remarkably decreased expression of proteins involved in the cellular transport of bile acids 
and consequently decreased intracellular concentrations of bile acids even though 
concentrations in the lumen and feces are expected to be increased due to the high fat 
content of WD.  Disrupted bile acid transport caused by WD provides a possible novel 
mechanism for initiative tumorigenesis underlying the WD-induced risk for CRC. 
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II. HYPERMETHYLATION IN LS ASSOCIATED TUMORIGENESIS (III) 
 
Disease phenotype, such as age of onset and tumor spectrum, vary considerably in 
human Lynch syndrome mutation carriers even among individuals that carry the same 
germline mutation. Phenotypical variation suggests the existence of other somatic driver 
events and implication of lifestyle factors on risk accumulation. Apart from genetic 
alterations, epigenetic changes play a major role in the initiation and progression of CRC. 
Epigenetic changes are particularly interesting since they are potentially reversible and 
can be modified by the environment. These changes can accumulate over time due to 
aging and many environmental factors such as diet.  
 
We utilized the unique features of LS, including increased tumor incidence and availability 
of tissue specimens gathered during colonoscopy surveillances, to study the temporal 
sequence of molecular changes that occur during different steps of tumorigenesis. 
Biopsies from normal colorectal mucosa together with blood samples were gathered from 
55 Finnish Lynch syndrome mutation carriers during colonoscopy screenings and 
colectomies performed in Helsinki University Central Hospital and Jyväskylä Central 
Hospital during 2011–2013 (Table 1/III). Out of these patients 39 (71%), 13 (24%) and 3 
(5%) were MLH1, MSH2 and MSH6 mutation carriers, respectively (Table 5). The 
prospective series was utilized to study methylation changes in the normal appearing 
colonic mucosa in association with age and previously diagnosed cancer. Furthermore, to 
study the methylation changes occurring during the adenoma-carcinoma progression 
sequence, all archival tubular and villous adenomas and carcinomas previously diagnosed 
for the LS patients were gathered from the nation-wide registry forming the retrospective 
series.  
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Table 5. Mutation specifications for patients included in study. 
Mutation Transcript HVGS protein  
No. of individuals 
with mutation 
MLH1 c.1732-2941_1896+432del NM_000249.3 p.Pro579_Glu633del 25 
MLH1 c.1975C>T NM_000249.3 p.Arg659* 2 
MLH1 c.320T>G NM_000249.3 p.Ile107Arg 3 
MLH1 c.454-1G>A NM_000249.3 p.Glu153Phefs*8 6 
MLH1 c.543C>G NM_000249.3 p.Gly181Gly, p.(Glu153Phefs*8) 1 
MLH1 c.546-2A>G NM_000249.3 p.Arg182Serfs*6 1 
MLH1 c.1039-1G>A NM_000249.3 p.Thr347Lysfs*8 1 
MSH2 c.1553_1554_delCA NM_000251.1 p.Gln518Leufs*10 3 
MSH2 c.1667_1671delGACTT NM_000251.1 p.Leu556Phefs*4 2 
MSH2 c.1737dupA NM_000251.1 p.Glu580Argfs*18 1 
MSH2 c.1777C>T NM_000251.1 p.Gln593* 2 
MSH2 c.1807 G>A NM_000251.1 p.Asp603Asn 2 
MSH2 c.696_697delTT NM_000251.1 p.Ser233Hisfs*22 2 
MSH2 c.2459-?_2802+?del NM_000251.1 p.? 1 
MSH6 c.2735G>A NM_000179.2 p.Trp912* 1 
MSH6 c.900dupG NM_000179.2 p.ys301Glufs*11 1 
MSH6 c.3013C>T NM_000179.2 p.Arg1005* 1 
 
 
Accumulation of molecular genetic defects during tumorigenesis 
 
MMR deficiency is proposed to accelerate rather that initiate tumor progression (62). The 
timing of somatic inactivation of the remaining wild-type allele was evaluated from 
colorectal specimens by studying MMR protein expression by IHC. All studied colorectal 
adenomas with high dysplasia and carcinomas from LS patients showed loss of MMR 
protein expression corresponding to the gene mutated in the germline (Table 6). Overall, 
loss of MMR protein expression increased along with dysplasia level (0% in normal 
mucosa, 50 – 68% in low dysplasia adenomas, and 100% in high dysplasia adenomas and 
carcinomas) suggesting that inactivation of MMR protein expression is a relatively late 
event in LS tumorigenesis. Of low dysplasia adenomas, only 68%, 67% and 50% showed 
loss of expression of MLH1, MSH2 and MSH6 mutation carriers, respectively (Table 6). 
Corresponding frequencies of adenomas with low dysplasia showed MSI (Table 6). 
Specifically, MSI analysis performed with mononucleotide repeat markers BAT25 and 
BAT26 showed that all MMR deficient adenomas and carcinomas were microsatellite 
unstable with one exception (adenoma with low dysplasia). All low dysplasia adenomas 
that retained MMR protein expression were microsatellite-stable. The fact that almost half 
of the low dysplasia adenomas were microsatellite-stable and retained MMR expression 
suggests the existence of other somatic driver events that precede inactivation of wild-type 
allele and induce polyp formation in LS.  
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Our findings are consistent with a previous study by Yurgelun et al. that demonstrate a 
significant association between the likelihood of an MMR deficient phenotype and 
increased size in LS-associated adenomas (297). Moreover, frequent occurrence of MMR 
deficient crypt foci observed in non-tumorous mucosa of LS mutations carriers indicates a 
high frequency of biallelic MMR gene inactivation, which is in sharp contrast with the 
relatively low number of clinically manifest adenomas and carcinomas in LS (298). These 
observations together highlight the necessity of other tumorigenic events that may arise 
before or after MMR gene activation independently of MMR status. 
 
Promoter methylation of MMR genes was studied as a possible cause of the “second hit” 
in MMR deficient tumors. A previous study by Auclair et al. suggested that MLH1 promoter 
methylation induces gene inactivation in a density-dependent pattern, whereas low-level 
methylation in unlikely to reduce gene expression (299). In our investigation, methylation 
of MLH1 was mostly detected in the distal promoter (region A), which has no direct 
association with protein loss (261). This region was found to be methylated in 30%, 31% 
and 60% of low-grade adenomas, high-grade adenomas and carcinomas, respectively. 
Methylation of region C, which is most commonly associated with protein loss and MSI, 
was detected in one high dysplasia adenoma (1/13), indicating that the corresponding 
allele may be silenced by hypermethylation. In summary, hypermethylation of MLH1 allele 
region C was detected in 1/42 (2%) of all tumors with silenced MLH1 protein. These 
results are in line with previous investigations that have reported inactivation of MLH1 in 
association with hypermethylation of region C in a small but definitive proportion of LS 
tumors (2-15%) (64, 116, 117). No methylation was detected in the promoter regions of 
MSH2 and MSH6. KRAS activating mutations are considered to occur during the early 
stages of the adenoma-carcinoma progression sequence in association with CIN 
phenotype in particular (45). Frequency of KRAS mutations was 8%, 25% and 30% in low 
dysplasia adenomas, high dysplasia adenomas and carcinomas, respectively, which 
indicates increased frequency of mutations along with dysplasia, complying with 
observations from sporadic adenomas (300). 
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Table 6. Molecular characteristics of tumors included in study III. 
          
Adenoma      
low dysplasia 
Adenoma      
high dysplasia Carcinoma     
Age at 
diagnosis   54 (32-69) 49 (25-74) 52 (31-74) 
Decreased 
expression of    
MMR protein  
MLH1 17/25 (68%) 13/13 (100%) 12/12 (100%)
MSH2 4/6 (67%) 1/1 (100%) 3/3 (100%) 
MSH6 1/2 (50%)      -  5/5 (100%) 
Total 22/33 (67%) 14/14 (100%) 20/20 (100%)
MSI 
MLH1 13/21 (62%) 12/12 (100%) 12/12 (100%)
MSH2 2/4 (50%) 1/1 (100%) 3/3 (100%) 
MSH6 1/2 (50%)  -  5/5 (100%) 
Total 16/27 (59%) 13/13 (100%) 20/20 (100%)
1CIMP 
MLH1 4/21 (19%) 2/12 (25%) 6/12 (50%) 
MSH2 0/4 (0%) 0/1 (0%) 0/3 (0%) 
MSH6 0/2 (0%)  -  4/5 (80%) 
Total 4/27 (15%) 2/13 (15%) 10/20 (50%) 
Mutated KRAS 
MLH1 1/19 (5%) 3/11 (27%) 3/12 (25%) 
MSH2 1/4 (25%) 0/1  (0%) 1/3 (33%) 
MSH6 0/2 (0%)  -  2/5 (40%) 
Total 2/25 (8%) 3/12 (25%) 6/20 (30%) 
1 CIMP classification was performed according to the Weisenberger criteria 
 
 
 
Hypermethylation in pre-malignant and malignant lesions 
 
Colorectal cancer is known to develop as a result of accumulation of genetic and 
epigenetic defects. Previous studies in sporadic CRC have demonstrated that promoter 
hypermethylation of tumorsuppressor genes can act as an alternative mechanism to 
mutations that causes transcriptional silencing (301, 302). Promoter methylation has been 
detected in CRC associated normal colonic mucosa and ACF which suggests it to occur 
as an early event in the colonic adenoma-carcinoma progression sequence (303, 304). 
The importance of CpG island hypermethylation in hereditary colorectal cancer syndromes 
such as Lynch syndrome remains unknown. 
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Aberrant CpG island methylation, previously associated mainly with sporadic CRC, gives 
rise to CpG island methylator phenotype (CIMP) (6). CIMP tumors are thought to form a 
distinct subtype of colorectal tumors that may be more responsive to demethylating agents 
used for chemoprevention (305). Eight genes previously associated with CIMP 
(CACNA1G, IGF2, NEUROG1, RUNX3, SOCS1, CDKN2A, MLH1 and CRABP1) were 
used to study methylation changes in pre-malignant and malignant colonic lesions 
gathered from LS patients. Frequency of hypermethylation in different tissue specimens 
was calculated separately for each gene (Fig.16). Hypermethylation in tumor tissues was 
evaluated against probe-specific thresholds derived from normal colonic mucosa.  As no 
consensus criteria exists for scoring CIMP, tumors were classified as CIMP-positive and 
non-CIMP according to two alternative CIMP marker panels from literature (84, 90). The 
frequency of CIMP-positive tumors increased from normal colonic mucosa to adenomas 
with low dysplasia to adenomas with high dysplasia and carcinomas regardless of which 
criteria were used. In summary, 4–15% of LS associated low dysplasia adenomas, 23% of 
high dysplasia adenomas and 25–50% of LS colorectal carcinomas could be classified as 
CIMP-positive depending on which markers and criteria were used (Fig.2/III). These 
results are consistent with previous investigations that have addressed hypermethylation 
of tumor suppressor genes in LS and sporadic colorectal adenomas (306, 307). 
 
Highest frequency of hypermethylation was observed in the high dysplasia adenomas and 
carcinomas (Fig.13). Out of the eight studied CIMP markers the highest frequencies of 
hypermethylation in tumors were observed in IGF2, NEUROG1, MLH1 and CRABP1. 
Hypermetylation frequency of IGF2 and NEUROG1 was significantly increased in all tumor 
types when compared to normal colonic tissue whereas the frequencies of methylated 
MLH1 and CRABP1 were only increased in carcinomas. Interestingly, a significant 
increase in IGF2 (68%, p?0.001) and NEUROG1 (48%, p?0.001) methylation was 
observed already in the low dysplasia adenomas (Fig.16), which indicates that methylation 
of these genes is an early event and could be further studied as potential early marker for 
CIMP and colonic oncogenesis. 
 
Additionally, a custom-designed MS-MLPA kit was compiled to study methylation changes 
in seven additional candidate genes (DKK1, SFRP1, SFRP2, SFRP5, CDH1, HOXD1 and 
SLC5A8) previously associated with early colonic oncogenesis. Reduced mRNA 
expression of these genes accompanied by increased promoter methylation was detected 
in a previous study performed in our group using the normal colonic mucosa of Mlh1+/- 
mice fed by Western-style diet (7). Methylation of two secreted frizzled-related proteins 
SFRP1 and SFRP2 were found to be significantly increased in high dysplasia adenomas 
and carcinomas compared to normal colon (Fig.13). Hypermethylation of SFRP2 was 
found to be significantly increased in all tumor types when compared to normal tissue, 
including adenomas with low dysplasia (37%, p=0.042). Significantly increased 
hypermethylation frequencies for SFRP1 were only observed in high dysplasia adenomas 
(67%, p=0.001) and carcinomas (67%, p=0.001) (Fig.13).  
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To evaluate the functional significance of methylation on gene expression, mRNA profiling 
of colorectal, endometrial and ovarian cancer cell lines treated with demethylating agent 5-
aza-CdR and histone deacetylase inhibitor TSA. Microarray analysis revealed consistent 
treatment-induced upregulation of SFRP1 (1.8 - 7.2 fold) in the MMR deficient cell lines 
HCT15, HCT116 and HEC59 analogous to LS associated CRC and endometrial cancer 
whereas SFRP2 was found to be significantly upregulated (1.9 fold) mainly in HCT116. 
Moreover, methylation and expression of SFPR1 (r= -0.69, p=0.001) and SFRP2 (r= -0.66, 
p=0.002) were found to be inversely correlated in cancer cell lines (treated and untreated) 
and corresponding normal tissues which suggests methylation to have a significant 
relevance in the expression of these genes. 
 
In the normal colonic epithelial cells SFRPs function as negative regulators of Wnt 
signalling pathway that inhibit binding of WNT proteins to their receptor frizzled (FRZ) 
(308-310). Loss of SFRP protein expression during early stages of tumorigenesis results in 
abnormal activation of Wnt pathway (311). Transcriptional silencing of SFRPs caused by 
promoter hypermethylation promotes Wnt signalling  through activation of the APC protein 
complex which induces cell proliferation and formation of ACF (312). Frequent promoter 
hypermethylation and gene silencing of the SFRP gene family members have been 
detected in ACF and primary colon cancer (313). Interestingly, promoter hypermethylation 
together with simultaneous reduction in gene expression has been observed in both CIMP-
H and non-CIMP tumors, which indicates that aberrant methylation and silencing of SFRPs 
genes can occur in colorectal tumors irrespective of their molecular subtype (85). 
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Fig.16. Frequency of hypermethylated genes in different colorectal specimens. Pairwise 
comparisons between hypermethylation frequency in tumors against colonic mucosa were 
tested for statistical significance (*p ? 0.05) by Fisher’s exact test. 
 
 
Field defects in normal appearing colonic mucosa 
 
Field defects are described as clonal abnormalities in the epithelial gene expression that 
precede and predispose to development of cancer and may cause simultaneous 
occurrence of multiple tumors (314). Previous studies have demonstrated genetic and 
epigenetic alterations in the macroscopically normal colonic mucosa that do not produce a 
morphological change but predispose to malignant transformation (315, 316). Field defects 
are suggested to occur in the immediate vicinity of the tumor or alternatively in a more 
widespread manner in a form of discrete patches (294, 304). Widespread changes have 
been suggested to be caused by dietary exposure as a consequence of interplay between 
underlying genetic defects and differences in luminal factors such as bile acids along the 
colon (294). Hence, some areas would be more susceptible to carcinogens found in the 
colonic lumen. Identification of such fields would be of clinical relevance since they provide 
insight to the earliest stages of CRC development and potential markers for risk 
assessment.  
 
Colorectal cancer risk increases with age and aging itself is known to associate with 
accumulation of DNA methylation in human normal colonic mucosa (317-320). Increased 
methylation in association with aging has been detected in normal appearing colonic tissue 
in a subset of tumor suppressor genes which often become more substantially methylated 
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during neoplastic progression (321-323). Even though causes of age-related methylation 
are unknown, it is proposed that environmental exposure and diet may play a role together 
with genetic predisposing factors (324). In our investigation, a moderate to strong positive 
correlation between normal colonic mucosa DNA methylation and age at biopsy was 
observed in CpG islands of IGF2, NEUROG1, SFRP1, SFRP2 and SLC5A8 (Fig.S3/III). 
No age-related correlation was observed in MLH1 region C methylation. 
 
Possible carcinogenic fields were investigated in the normal appearing colonic mucosa in 
association with age and previously diagnosed cancer. Methylation of CIMP markers and 
candidate genes were analyzed from normal colonic mucosa biopsies by MS-MLPA. 
Patients were divided into four groups depending on age at biopsy and absence vs. 
presence of (previous or concurrent) CRC (groups 1-4). The first two groups (groups 1-2) 
included patients that were 50 years old or below and consisted of 22 patients that had not 
been diagnosed with CRC (low-risk mucosa) and 6 individuals with previouly or 
concurrently diagnosed CRC (high-risk mucosa). The last two groups (groups 3-4) 
consisted of patients above 50 years old and included 17 individuals that had not been 
diagnosed with CRC and 10 individuals with CRC, respectively. Duration between CRC 
diagnosis and time of biopsy was 5,1 years (range  0-11,5) in group 2 and 5,5 years 
(range 0-12,4) in group 4. Average age at biopsy was comparable in each group: 35 
(range 26-50), 43 (range 39-48), 61 (range 51-75) and 63 (range 51-74), respectively. 
 
When the effect of CRC on CIMP marker methylation in normal colonic mucosa was 
studied within the age two groups (?50 and above 50), no significant differences were 
observed between low-risk mucosa vs. high-risk mucosa methylation. However, a 
significant increase in IGF2 and NEUROG1 methylation was detected when comparing the 
age groups with each other (?50 vs. above 50) indicating age-dependent methylation 
(Fig.S4/III). In mutation carriers above 50 years old, two markers from the candidate gene 
panel SFRP1 (p < 0.0001) and SLC5A8 (p= 0.007) revealed a significantly elevated 
average degree of methylation in high-risk mucosa group when compared to all other 
groups which indicated a potential field defect (Fig.4/III). Methylation and silencing of 
SLC5A8 is frequently detected in ACF and CRCs (325). SLC5A8, that encodes a sodium 
transporter and is a member of the sodium solute symporter family (SLC5), mediates 
directly the absorption of short-chain fatty acids (e.g butyrate) from the apical membrane of 
the intestinal tract into the colon (326, 327). Butyrate is a by-product of bacterial 
fermentation and has been proven to have anti-proliferative control of the cell cycle 
through its effect on histone acetylation (328).  
 
Our findings are consistent with a recent study by Luo et al. that reported increased 
genome-wide DNA methylation content in (sporadic) CRC-associated normal colonic 
mucosa compared to normal mucosa from cancer-free individuals (329). These results 
together with our data urge further studies with prospective study settings to confirm 
whether the methylation state of normal appearing colonic mucosa could predispose to 
development of CIMP-positive tumors and predict the risk for CRC.  
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Differences between low-risk and high-risk mucosa were small although statistically 
significant. Since observed differencies in methylation between groups were small, 
sensitivity of MS-MLPA method was tested by analysing a dilution series with a decreasing 
amount of methylated control DNA (Fig.17). Results indicate that even 5% increase in 
methylation could reliably be detected in most cases indicating that observed differences 
were unlikely to be explained by e.g technical variation. SLC5A8 was discarded from 
analysis, since its methylation levels were not affected in the methylated and non-
methylated controls. 
 
 
 
Fig.17. MS-MLPA sensitivity. Sensitivity of the method was evaluated against a gradient of 
methylated DNA. 
 
 
It is difficult to discrimminate the molecular changes that are integral in driving cancer from 
innocent bystanders changes induced by aberrant DNA repair or defective apoptosis. 
Therefore, mechanistic studies are needed in order to elucidate early molecular drivers of 
CRC. Moreover, it has been concluded that malignant transformation is a results of 
accumulation of defects in several genes that have low individual effect by themselves 
(330). However, changes that occur during early stages of tumorigenesis are more likely to 
act as driver events whereas later changes may simply reflect the transformed phenotype. 
Epigenetic changes are particularly interesting, since they are potentially reversible and 
can be modified by pharmacological agents and diet unlike germline mutations. 
Idenfication of epigenetic changes underlying field defects could be utilized in 
chemoprevention prior the development of malignant lesions (331).  
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CONCLUSIONS  
 
 
The study on the effects of Western-style diet on the normal appearing colonic mucosa of 
mouse models for Lynch syndrome (Mlh1+/-) and sporadic CRC (Mlh1+/+) provided the 
following conclusions (I-II): 
 
? Quantitative proteomic analysis of histologically normal proximal colon mucosa 
revealed significant protein expression changes caused by Western-style diet and 
aging. 
? Proteomes were more consistently changed by diet and aging than by Mlh1 
genotype. 
? Significant up-regulation of genes associated with fatty acid catabolism reflected 
increased oxidative stress after 12 months of WD feeding which may induce DNA 
damage and eventually lead to cancer. 
? Analysis of the proteomic data of the Mlh1+/+ wild type mice indicated strong 
activation of proliferative processes and inactivation of apoptotic processes, two 
important driver events of cancer, in 12m and 18m WD mice in particular. 
? Expansion of proliferation zone was detected in the colonic crypts of 12m WD mice 
implicating increased risk for tumorigenesis. 
? Proteomics data coupled with measurement of bile acids in tissue specimens 
indicated down-regulation of bile acid sensing and transport together with 
decreased intracellular secondary bile acids in mice fed with WD, suggesting 
disrupted bile acid homeostasis. 
 
 
The analysis of molecular genetic changes in normal colonic mucosa biopsies and tumors 
of different stages of the adenoma-carcinoma progression sequence in human Lynch 
syndrome provided the following conclusions (III): 
 
? Expression of MMR protein corresponding to the gene mutated in the germline 
decreased along with dysplasia in tumors but occurred as a relatively late event in 
the tumor progression sequence, suggesting the presence of other somatic events 
that drive neoplastic transformation. 
? Methylation of CIMP marker loci and selected candidate genes increased together 
with dysplasia and preceded inactivation of MMR in some low dysplasia adenomas 
which indicated that methylation occurs as an early event in LS-associated 
tumorigenesis.  
? A proportion of low dysplasia adenomas could already be classified CIMP-positive 
and the frequency of CIMP further increased in high dysplasia adenomas and 
carcinomas which highlights the importance and early appearance of epigenetic 
alterations in LS in general. 
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? Significant increase in the average degree of methylation of two candidate genes 
(SFRP1 and SLC5A8) was observed in normal colonic mucosa biopsies from 
patients with CRC (high-risk mucosa) compared to those without (low-risk mucosa) 
indicating a possible carcinogenic “field”. 
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FUTURE PROSPECTS 
 
In light of the presented thesis, future prospects for the studies regarding the diet 
experiment may include: 
 
? DNA methylome analysis of Western-style diet effects in normal colonic mucosa of 
mice to address possible epigenome-wide effects of the diet. 
? Metabolite analysis of the normal colonic tissue to provide a possible mechanistic 
link for the changes detected in the proteome.  
? Analysis of apoptotic processes in normal colonic mucosa in relation to diet. 
? In depth analysis of the possible oncogenic effects of the disrupted bile acid 
transport and the activity of nuclear bile acid receptor FXR. 
 
The gathering of clinical samples from Lynch syndrome patients continues in collaboration 
with surgeons. On-going studies and future prospects for this project include: 
 
? Validation of preliminary results of possible field changes regarding normal colonic 
mucosa methylation in an extended sample set including tissue specimens 
gathered from the same individuals in follow-up colonoscopies. 
? Targeted sequencing of key oncogenes and tumor suppressor genes from tumor-
specimens in aim to detect possible driver mutations in genes encoding for 
epigenetic modifiers that may contribute to observed methylation changes. 
? Utilization of clinical specimens to validate markers for disrupted bile acid pathway 
in normal colonic mucosa. 
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